



Afghanistan - HTA Country/Area Profile¹



Institutions & governance

Question	Response
Has a systematic process to support healthcare decision-making?	No
Please describe your health-care decision making process below.	There is a department by the name of General Directorate Monitoring, Evaluation and Health Information System (GDMEHIS), which collects the data from health facilities and based on the data the decisions are made for health services, but not for health technologies.
Can you indicate whether there are plans for implementing a systematic formal process and if so, what that time-frame is?	There will be a process in place in 3-5 years
Any prioritization criteria used to determine which health technologies and interventions are considered in government health schemes in the country?	Yes
Is evidence collected for making decisions about the inclusion or exclusion of health technologies and interventions?	Yes
Are there any formal or informal procedures, rules, thresholds, or laws that factor in to the decision-making related to health technologies and interventions?	Yes

Question	Entity	Title/Function	Response
Entities(e.g. organizations/individuals/officials) involved in decisions regarding inclusion or exclusion of health technologies and interventions:	Entity 1	Title of Entity	DGMEHIS
		Functions Performed	Data collection and analysis
	Entity 2	Title of Entity	Curative Medicine
		Functions Performed	Proposing interventions
	Entity 3	Title of Entity	Grant and Procurement Management Unit
		Functions Performed	Procurement
	Entity 4	Title of Entity	Health Economy and Finance Dept
		Functions Performed	Costing of the services
	Entity 5	Title of Entity	Performance Management Unit
		Functions Performed	Monitoring of the services

Question	Option	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Afghanistan - HTA Country/Area Profile¹



Question	Response
Provisions for revising decisions about health technologies and interventions once they are made.	No
Mechanism for translation or contextualization of evidence?	No
Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production capability	Rank 1	Dedicated human resources
	Rank 2	Institutionalization of HTA		Rank 2	Budget availability
	Rank 3	Political support		Rank 3	Data Availability
	Rank 4	Qualified human resources		Rank 4	Knowledge of methods
	Rank 5	Mandate from Policy Authority		Rank 5	Other Issues
	Rank 6	Other Issues			

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Algeria - HTA Country/Area Profile¹



Institutions & governance

Question	Response
Has a systematic process to support healthcare decision-making?	No
Please describe your health-care decision making process below.	The health-care decision making process relates only to the some medical products (medicines) reimbursement by the two health insurance agencies (CNAS and CASNOS). These two agencies study and review information submitted by pharmaceutical industry with regard to medicines submitted for reimbursement. Other technologies and intervention are not evaluated in a such mechanism.
Can you indicate whether there are plans for implementing a systematic formal process and if so, what that time-frame is?	There is no plan to implement such a process
Any prioritization criteria used to determine which health technologies and interventions are considered in government health schemes in the country?	N/R
Is evidence collected for making decisions about the inclusion or exclusion of health technologies and interventions?	N/R
Are there any formal or informal procedures, rules, thresholds, or laws that factor in to the decision-making related to health technologies and interventions?	N/R

Question	Entity	Title/Function	Response
Entities(e.g. organizations/individuals/officials) involved in decisions regarding inclusion or exclusion of health technologies and interventions:	Entity 1	Title of Entity	Ministry of Health
		Functions Performed	these entities are involved only in the reimbursement mechanism of medicines
	Entity 2	Title of Entity	Ministry of Work
		Functions Performed	N/R
	Entity 3	Title of Entity	Ministry of industry
		Functions Performed	N/R
	Entity 4	Title of Entity	Ministry of Trade
		Functions Performed	N/R
	Entity 5	Title of Entity	Ministry of Interior affaires
		Functions Performed	N/R

Question	Option	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	No

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Algeria - HTA Country/Area Profile¹



Functions for which decision-making information is gathered?	Other	reimbursement mechanisms of medicines
--	-------	---------------------------------------

Question	Response
Provisions for revising decisions about health technologies and interventions once they are made.	N/R
Mechanism for translation or contextualization of evidence?	N/R
Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Political support	Barriers to Production capability	Rank 1	Dedicated human resources
	Rank 2	Awareness/Advocacy of the importance of HTA		Rank 2	Data Availability
	Rank 3	Institutionalization of HTA		Rank 3	Knowledge of methods
	Rank 4	Mandate from Policy Authority		Rank 4	Other Issues
	Rank 5	Qualified human resources		Rank 5	Budget availability
	Rank 6	Other Issues			

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Argentina - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	Yes
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	CONETEC	CONETEC	CONETEC	CONETEC	CONETEC
Assessment	CONETEC	CONETEC	CONETEC	CONETEC	CONETEC
Recommendation	CONETEC	CONETEC	CONETEC	CONETEC	CONETEC

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	Yes	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R
	Department/Ministry of Health	No	Do you assess impact?	N/R
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	Yes		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R	Are any resources received through private funding?	N/R
Allocated public sector budget?	No	If so, what percentage?	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Argentina - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	8



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/R
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	No	Yes	Yes	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Institutionalization of HTA
	Rank 2	Political support
	Rank 3	Other Issues
	Rank 4	N/R
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Data Availability
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Austria - HTA Country/Area Profile¹



Institutions & governance

Question	Response
Has a systematic process to support healthcare decision-making?	No
Please describe your health-care decision making process below.	decisions on costly interventions are made on the regional level in regional hospitals. Only for the hospital benefit catalogue there is a national process in place, but not for drugs.
Can you indicate whether there are plans for implementing a systematic formal process and if so, what that time-frame is?	There will be a process in place in 1-2 years
Any prioritization criteria used to determine which health technologies and interventions are considered in government health schemes in the country?	Yes
Is evidence collected for making decisions about the inclusion or exclusion of health technologies and interventions?	Yes
Are there any formal or informal procedures, rules, thresholds, or laws that factor in to the decision-making related to health technologies and interventions?	Yes

Question	Entity	Title/Function	Response
Entities(e.g. organizations/individuals/officials) involved in decisions regarding inclusion or exclusion of health technologies and interventions:	Entity 1	Title of Entity	MoH
		Functions Performed	unlimited
	Entity 2	Title of Entity	regional public hospitals
		Functions Performed	unlimited
	Entity 3	Title of Entity	health insurances
		Functions Performed	unlimited
	Entity 4	Title of Entity	AIHTA
		Functions Performed	N/R
	Entity 5	Title of Entity	N/R
		Functions Performed	N/R

Question	Option	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	N/R
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	N/R
	Objectives for pay-for-performance schemes	N/R
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Question	Response
Provisions for revising decisions about health technologies and interventions once they are made.	Yes

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Austria - HTA Country/Area Profile¹



Mechanism for translation or contextualization of evidence?	No
Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Political support
	Rank 2	Mandate from Policy Authority
	Rank 3	Awareness/Advocacy of the importance of HTA
	Rank 4	Qualified human resources
	Rank 5	Institutionalization of HTA
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production capability	Rank 1	Data Availability
	Rank 2	Budget availability
	Rank 3	Dedicated human resources
	Rank 4	Knowledge of methods
	Rank 5	N/R

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Bangladesh - HTA Country/Area Profile¹



Institutions & governance

Question	Response
Has a systematic process to support healthcare decision-making?	No
Please describe your health-care decision making process below.	N/R
Can you indicate whether there are plans for implementing a systematic formal process and if so, what that time-frame is?	There is no plan to implement such a process
Any prioritization criteria used to determine which health technologies and interventions are considered in government health schemes in the country?	No
Is evidence collected for making decisions about the inclusion or exclusion of health technologies and interventions?	No
Are there any formal or informal procedures, rules, thresholds, or laws that factor in to the decision-making related to health technologies and interventions?	No

Question	Entity	Title/Function	Response
Entities(e.g. organizations/individuals/officials) involved in decisions regarding inclusion or exclusion of health technologies and interventions:	Entity 1	Title of Entity	Director General of Health Services
		Functions Performed	Identifying Intervention and Making Recommendation
	Entity 2	Title of Entity	Director General of Medical Education
		Functions Performed	Identifying Intervention and Making Recommendation
	Entity 3	Title of Entity	Director General of Family Planning
		Functions Performed	Identifying Intervention and Making Recommendation
	Entity 4	Title of Entity	Ministry of Health and Family Welfare
		Functions Performed	Making Recommendation
	Entity 5	Title of Entity	N/R
		Functions Performed	N/R

Question	Option	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Question	Response
Provisions for revising decisions about health technologies and interventions once they are made.	No
Mechanism for translation or contextualization of evidence?	No

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Bangladesh - HTA Country/Area Profile¹



Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Qualified human resources
	Rank 2	Awareness/Advocacy of the importance of HTA
	Rank 3	Institutionalization of HTA
	Rank 4	Mandate from Policy Authority
	Rank 5	Political support
	Rank 6	Other Issues

Question	Ranking	Response
Barriers to Production capability	Rank 1	Dedicated human resources
	Rank 2	Budget availability
	Rank 3	Knowledge of methods
	Rank 4	Data Availability
	Rank 5	Other Issues

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Belarus - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Republican Unitary Enterprise "Center for Expertise and Testing in Health Care"	Ministry of Health of the Republic of Belarus	Republican Unitary Enterprise "Center for Expertise and Testing in Health Care"	Healthcare Institution "National Anti-Doping Laboratory"; Republican Unitary Enterprise "Center for Expertise and Testing in Health Care"	Republican Center for Hygiene, Epidemiology and Public Health; Republican Scientific and Practical Center "Traumatology and Orthopedics"; Republican Scientific and Practical Center "Cardiology"; Republican Unitary Enterprise "Scientific and Practical Center for Hygiene"; Republican Scientific and Practical Center for Oncology and Medical Radiology named after N.N. Alexandrova

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Belarus - HTA Country/Area Profile



Assessment	Republican Unitary Enterprise "Management Company of the Belfarmprom Holding"; The republican Trade and production unitary enterprise "Belpharmacia"; Republican Unitary Enterprise "Center for Expertise and Testing in Health Care"	Republican Scientific and Practical Center for Medical Technologies, Informatization, Management and Economics of Health Care	The Republican Scientific and Practical Center of Medical Technologies, Informatization, Management and Economics of Public Health (RSPC MT)	Healthcare Institution "National Anti-Doping Laboratory"	Republican Center for Hygiene, Epidemiology and Public Health; Republican Scientific and Practical Center "Traumatology and Orthopedics"; Republican Scientific and Practical Center "Cardiology"; Republican Unitary Enterprise "Scientific and Practical Center for Hygiene"; Republican Scientific and Practical Center for Oncology and Medical Radiology named after N.N. Alexandrova
Recommendation	Ministry of Health of the Republic of Belarus	Ministry of Health of the Republic of Belarus	Ministry of Health of the Republic of Belarus	Ministry of Health of the Republic of Belarus	Ministry of Health of the Republic of Belarus

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	Yes
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	More than 100	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	Yes	If so, what percentage?	N/A



Assessments

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Belarus - HTA Country/Area Profile



Question	Response
How long does the assessment process take on average?	6-12 months
In the last 12 months, approximately how many assessments were performed?	75



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	Yes
If so, what is it?	Not applicable because the threshold value is set differentially
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	Yes
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	Yes	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Institutionalization of HTA		Rank 2	Data Availability
	Rank 3	Political support		Rank 3	Knowledge of methods
	Rank 4	Qualified human resources		Rank 4	Dedicated human resources
	Rank 5	Mandate from Policy Authority		Rank 5	Other Issues
	Rank 6	Other Issues			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Belgium - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	N/R
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	N/R
	Objectives for pay-for-performance schemes	N/R
	Design of Health Benefit Packages	N/R
	Public Procurement of Medicines	N/R
	Protocols for public health programmes	N/R
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	KCE-INAMI	KCE-INAMI	KCE-INAMI	KCE-INAMI	KCE
Assessment	KCE-INAMI	KCE-INAMI	KCE-INAMI	KCE-INAMI	KCE
Recommendation	KCE-INAMI (recommandations) - Politiques (décision)	KCE-INAMI (recommandations) - Politiques (décision)	KCE-INAMI (recommandations) - Politiques (décision)	KCE-INAMI (recommandations) - Politiques (décision)	KCE-INAMI (recommandations) - Politiques (décision)

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	N/R	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	N/R	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	N/R	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	N/R	Do you assess impact?	No
	National Health Service	N/R		
	Patient Organizations	N/R		
	Civil Society	N/R		
	Other	Yes		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Belgium - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20
Allocated public sector budget?	Yes

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	6-12 months
In the last 12 months, approximately how many assessments were performed?	5



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	N/R	Yes	Yes	N/R	N/R



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Mandate from Policy Authority
	Rank 2	Awareness/Advocacy of the importance of HTA
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Other Issues
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Belize - HTA Country/Area Profile¹



Institutions & governance

Question	Response
Has a systematic process to support healthcare decision-making?	No
Please describe your health-care decision making process below.	N/R
Can you indicate whether there are plans for implementing a systematic formal process and if so, what that time-frame is?	N/R
Any prioritization criteria used to determine which health technologies and interventions are considered in government health schemes in the country?	N/R
Is evidence collected for making decisions about the inclusion or exclusion of health technologies and interventions?	No
Are there any formal or informal procedures, rules, thresholds, or laws that factor in to the decision-making related to health technologies and interventions?	Yes

Question	Entity	Title/Function	Response
Entities(e.g. organizations/individuals/officials) involved in decisions regarding inclusion or exclusion of health technologies and interventions:	Entity 1	Title of Entity	Ministry of Health
		Functions Performed	N/R
	Entity 2	Title of Entity	Medical insurance
		Functions Performed	N/R
	Entity 3	Title of Entity	N/R
		Functions Performed	N/R
	Entity 4	Title of Entity	N/R
		Functions Performed	N/R
	Entity 5	Title of Entity	N/R
		Functions Performed	N/R

Question	Option	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Question	Response
Provisions for revising decisions about health technologies and interventions once they are made.	No
Mechanism for translation or contextualization of evidence?	No

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Belize - HTA Country/Area Profile¹



Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Qualified human resources
	Rank 2	Awareness/Advocacy of the importance of HTA
	Rank 3	Mandate from Policy Authority
	Rank 4	Institutionalization of HTA
	Rank 5	Political support
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production capability	Rank 1	Dedicated human resources
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Benin - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Actor and Stakeholders	Actor and Stakeholders	Actor and Stakeholders	Actor and Stakeholders	Actor and Stakeholders
Assessment	Department of Pharmacies and Medicines	Directorate of Hospital Establishments	National Directorate of Public Health	Exploration and Diagnostic Department	Civil society, Consumers Association
Recommendation	Actor and Stakeholders	Actor and Stakeholders	Actor and Stakeholders	Actor and Stakeholders	Actor and Stakeholders

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	No	Do you assess impact?	Yes
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Benin - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20
Allocated public sector budget?	No

Question	Response
Are any resources received through private funding?	N/R
If so, what percentage?	N/R



Assessments

Question	Response
How long does the assessment process take on average?	1-3 months
In the last 12 months, approximately how many assessments were performed?	5



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	No
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	Yes	No	Yes	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Mandate from Policy Authority
	Rank 2	Political support
	Rank 3	Qualified human resources
	Rank 4	Institutionalization of HTA
	Rank 5	Awareness/Advocacy of the importance of HTA
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Data Availability
	Rank 3	Dedicated human resources
	Rank 4	Knowledge of methods
	Rank 5	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Bhutan - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	National Essential Medicine List

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Hospital & MoH	Hospital & MoH	Hospital & MoH	Hospital & MoH	MoH
Assessment	Hospital & MoH	Hospital, MoH	Hospital & MoH	Hospital & MoH	Hospital & MoH
Recommendation	MoH	MoH	MoH	MoH	MoH

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	N/R
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	Yes		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	1 to 5	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	Yes	If so, what percentage?	N/A

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Bhutan - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	3-6 months
In the last 12 months, approximately how many assessments were performed?	3



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	N/R
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	No	No	No	Yes	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Institutionalization of HTA
	Rank 2	Qualified human resources
	Rank 3	Awareness/Advocacy of the importance of HTA
	Rank 4	Mandate from Policy Authority
	Rank 5	Political support
	Rank 6	Other Issues

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Knowledge of methods
	Rank 2	Dedicated human resources
	Rank 3	Data Availability
	Rank 4	Budget availability
	Rank 5	Other Issues

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Bolivia (Plurinational State of) - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	National Committee for the Evaluation and Rational Use of Health Technologies CNET	National Committee for the Evaluation and Rational Use of Health Technologies CNET	National Committee for the Evaluation and Rational Use of Health Technologies CNET	National Committee for the Evaluation and Rational Use of Health Technologies CNET	National Committee for the Evaluation and Rational Use of Health Technologies CNET
Assessment	National Committee for the Evaluation and Rational Use of Health Technologies CNET	National Committee for the Evaluation and Rational Use of Health Technologies CNET	National Committee for the Evaluation and Rational Use of Health Technologies CNET	National Committee for the Evaluation and Rational Use of Health Technologies CNET	National Committee for the Evaluation and Rational Use of Health Technologies CNET
Recommendation	National Committee for the Evaluation and Rational Use of Health Technologies CNET	National Committee for the Evaluation and Rational Use of Health Technologies CNET	National Committee for the Evaluation and Rational Use of Health Technologies CNET	National Committee for the Evaluation and Rational Use of Health Technologies CNET	National Committee for the Evaluation and Rational Use of Health Technologies CNET

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Bolivia (Plurinational State of) - HTA Country/Area Profile



Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R
	Department/Ministry of Health	No	Do you assess impact?	N/R
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R	Are any resources received through private funding?	N/R
Allocated public sector budget?	No	If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Bolivia (Plurinational State of) - HTA Country/Area Profile



	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Mandate from Policy Authority		Rank 2	Data Availability
	Rank 3	Institutionalization of HTA		Rank 3	Knowledge of methods
	Rank 4	Political support		Rank 4	Dedicated human resources
	Rank 5	Qualified human resources		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Bosnia and Herzegovina - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		N/R

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Ministry of Health and social Welfare	Ministry of Health and social Welfare	Ministry of Health and social Welfare	Ministry of Health and social Welfare	Ministry of Health and social Welfare
Assessment	Ministry of Health and social Welfare	Ministry of Health and social Welfare	Ministry of Health and social Welfare	Ministry of Health and social Welfare	Ministry of Health and social Welfare
Recommendation	Ministry of Health and social Welfare	Ministry of Health and social Welfare	Ministry of Health and social Welfare	Ministry of Health and social Welfare	Ministry of Health and social Welfare

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Bosnia and Herzegovina - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	1 to 5
Allocated public sector budget?	I don't know

Question	Response
Are any resources received through private funding?	N/R
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	N/R
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	N/R
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	N/R
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Brazil - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	Yes
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	CONITEC / REBRATS	CONITEC / REBRATS	CONITEC / REBRATS	CONITEC / REBRATS	CONITEC / REBRATS
Assessment	CONITEC / REBRATS	CONITEC / REBRATS	CONITEC / REBRATS	CONITEC / REBRATS	CONITEC / REBRATS
Recommendation	CONITEC / REBRATS	CONITEC / REBRATS	CONITEC / REBRATS	CONITEC / REBRATS	CONITEC / REBRATS

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	Yes	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R
	Department/Ministry of Health	Yes	Do you assess impact?	N/R
	National Health Service	Yes		
	Patient Organizations	Yes		
	Civil Society	Yes		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Brazil - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	21 to 50
Allocated public sector budget?	Yes

Question	Response
Are any resources received through private funding?	N/R
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	70



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	N/R
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	Yes	Yes	Yes	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA
	Rank 2	Qualified human resources
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Dedicated human resources
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Brunei Darussalam - HTA Country/Area Profile¹



Institutions & governance

Question	Response
Has a systematic process to support healthcare decision-making?	No
Please describe your health-care decision making process below.	Currently through administrative arrangements.
Can you indicate whether there are plans for implementing a systematic formal process and if so, what that time-frame is?	There will be a process in place in 3-5 years
Any prioritization criteria used to determine which health technologies and interventions are considered in government health schemes in the country?	Yes
Is evidence collected for making decisions about the inclusion or exclusion of health technologies and interventions?	Yes
Are there any formal or informal procedures, rules, thresholds, or laws that factor in to the decision-making related to health technologies and interventions?	N/R

Question	Entity	Title/Function	Response
Entities(e.g. organizations/individuals/officials) involved in decisions regarding inclusion or exclusion of health technologies and interventions:	Entity 1	Title of Entity	Lead Clinicians / Experts
		Functions Performed	Identifying / Proposing Interventions
	Entity 2	Title of Entity	Drug Advisory Committee
		Functions Performed	Appraising evidence for introducing medications into formulary
	Entity 3	Title of Entity	Department of Policy and Planning
		Functions Performed	Assessing evidence and making recommendations
	Entity 4	Title of Entity	Department of Healthcare Technology
		Functions Performed	Assessing evidence and making recommendations for procurement of medical equipment
	Entity 5	Title of Entity	N/R
		Functions Performed	N/R

Question	Option	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	No
	Other	N/R

Question	Response
Provisions for revising decisions about health technologies and interventions once they are made.	N/R

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Brunei Darussalam - HTA Country/Area Profile¹



Mechanism for translation or contextualization of evidence?	N/R
Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Mandate from Policy Authority
	Rank 2	Qualified human resources
	Rank 3	Institutionalization of HTA
	Rank 4	Awareness/Advocacy of the importance of HTA
	Rank 5	Political support
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production capability	Rank 1	Dedicated human resources
	Rank 2	Data Availability
	Rank 3	Budget availability
	Rank 4	Knowledge of methods
	Rank 5	N/R

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Bulgaria - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	regulation of the price on medicine

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	NCPR	N/R	N/R	N/R	N/R
Assessment	NCPR	N/R	N/R	N/R	N/R
Recommendation	NCPR	N/R	N/R	N/R	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	No	Do you assess impact?	N/R
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Bulgaria - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	1 to 5
Allocated public sector budget?	Yes

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	3-6 months
In the last 12 months, approximately how many assessments were performed?	53



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	Yes	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	N/R
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Other Issues
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Burkina Faso - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	National Agency for Pharmaceutical Regulation (ANRP)	General Directorate of Healthcare Provision (DGOS)	National Agency for Pharmaceutical Regulation (ANRP)	National Agency for Pharmaceutical Regulation (ANRP)	General Directorate of Public Health (DGSP)
Assessment	National Agency for Pharmaceutical Regulation (ANRP)	General Directorate of Healthcare Provision (DGOS)	National Agency for Pharmaceutical Regulation (ANRP)	National Agency for Pharmaceutical Regulation (ANRP)	General Directorate of Public Health (DGSP)
Recommendation	National Agency for Pharmaceutical Regulation (ANRP)	General Directorate of Healthcare Provision (DGOS)	National Agency for Pharmaceutical Regulation (ANRP)	National Agency for Pharmaceutical Regulation (ANRP)	General Directorate of Public Health (DGSP)

Question	Options	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No
	Executive Board of the HTA or decision-making body	No
	Director of the HTA or decision-making body	Yes
	Department/Ministry of Health	Yes
	National Health Service	No
	Patient Organizations	No
	Civil Society	No
	Other	N/R

Question	Response
Mechanism for translation or contextualization of evidence?	Yes
Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
Do you assess impact?	Yes

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Burkina Faso - HTA Country/Area Profile



Available Resources

Question	Response
How many professional staff (FTE) are involved in the HTA body?	21 to 50
Allocated public sector budget?	Yes

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	3-6 months
In the last 12 months, approximately how many assessments were performed?	4



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	Yes



Barriers

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Burkina Faso - HTA Country/Area Profile



Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	N/R	Barriers to Production Capability	Rank 1	N/R
	Rank 2	N/R		Rank 2	N/R
	Rank 3	N/R		Rank 3	N/R
	Rank 4	N/R		Rank 4	N/R
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Burundi - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		N/R
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		I don't know

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Ministry of Public Health, WHO, USAID, Global Fund, World Bank	Ministry of Public Health, WHO, USAID, Global Fund, World Bank	Ministry of Public Health, WHO, USAID, Global Fund, World Bank	Ministry of Public Health, WHO, USAID, Global Fund, World Bank	Ministry of Public Health, WHO, USAID, Global Fund, World Bank
Assessment	Ministry of Public Health, WHO, USAID, Global Fund, World Bank, European Union	Ministry of Public Health, WHO, USAID, Global Fund, World Bank, European Union	Ministry of Public Health, WHO, USAID, Global Fund, World Bank, European Union	Ministry of Public Health, WHO, USAID, Global Fund, World Bank, European Union	Ministry of Public Health, WHO, USAID, Global Fund, World Bank, European Union
Recommendation	Government, technical and financial partners, civil society	Government, technical and financial partners, civil society	Government, technical and financial partners, civil society	Government, technical and financial partners, civil society	Government, technical and financial partners, civil society

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Burundi - HTA Country/Area Profile



Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R
	Department/Ministry of Health	Yes	Do you assess impact?	N/R
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R	Are any resources received through private funding?	N/R
Allocated public sector budget?	I don't know	If so, what percentage?	N/R



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	N/R
Do you have a database of health technology costs or prices?	N/R
Is there an officially endorsed cost-effectiveness threshold?	N/R
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Burundi - HTA Country/Area Profile



	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	N/R
	Rank 2	Qualified human resources		Rank 2	N/R
	Rank 3	N/R		Rank 3	N/R
	Rank 4	N/R		Rank 4	N/R
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Cabo Verde - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	N/R	N/R	N/R	N/R	N/R
Assessment	GAF	DNS	DGPOG	GAF/DNS	DNS
Recommendation	GAF	DNS	DGPOG	GAF/DNS	DNS

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R
	Department/Ministry of Health	Yes	Do you assess impact?	N/R
	National Health Service	Yes		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	No	If so, what percentage?	N/A

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Cabo Verde - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	N/R
Do you have a database of health technology costs or prices?	N/R
Is there an officially endorsed cost-effectiveness threshold?	N/R
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	N/R
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	N/R
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Canada - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	Yes
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	N/R	N/R	N/R	N/R	N/R
Assessment	N/R	N/R	N/R	N/R	N/R
Recommendation	N/R	N/R	N/R	N/R	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R
	Department/Ministry of Health	No	Do you assess impact?	N/R
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	Yes		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	More than 100	Are any resources received through private funding?	N/R
Allocated public sector budget?	N/R	If so, what percentage?	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Canada - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	N/R
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/R
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	No	No	Yes	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	N/R
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	N/R
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R
	Rank 6	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Chad - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	N/R	N/R	N/R	N/R	N/R
Assessment	N/R	N/R	N/R	N/R	Mass vaccination campaign
Recommendation	N/R	N/R	N/R	N/R	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	Yes	Do you assess impact?	N/R
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Chad - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R
Allocated public sector budget?	I don't know

Question	Response
Are any resources received through private funding?	N/R
If so, what percentage?	N/R



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	N/R
Do you have a database of health technology costs or prices?	N/R
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA
	Rank 2	Political support
	Rank 3	Qualified human resources
	Rank 4	Institutionalization of HTA
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Knowledge of methods
	Rank 2	Dedicated human resources
	Rank 3	Data Availability
	Rank 4	Budget availability
	Rank 5	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Chile - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	Yes
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Department of Health Technology Assessment and Evidence-Based Health	Department of Health Technology Assessment and Evidence-Based Health	Department of Health Technology Assessment and Evidence-Based Health	Department of Health Technology Assessment and Evidence-Based Health	Department of Health Technology Assessment and Evidence-Based Health
Assessment	Department of Health Technology Assessment and Evidence-Based Health	Department of Health Technology Assessment and Evidence-Based Health	Department of Health Technology Assessment and Evidence-Based Health	Department of Health Technology Assessment and Evidence-Based Health	Department of Health Technology Assessment and Evidence-Based Health
Recommendation	Department of Health Technology Assessment and Evidence-Based Health	Department of Health Technology Assessment and Evidence-Based Health	Department of Health Technology Assessment and Evidence-Based Health	Department of Health Technology Assessment and Evidence-Based Health	Department of Health Technology Assessment and Evidence-Based Health

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Chile - HTA Country/Area Profile



Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R
	Department/Ministry of Health	No	Do you assess impact?	N/R
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20	Are any resources received through private funding?	N/R
Allocated public sector budget?	Yes	If so, what percentage?	N/R



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	350



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	N/R
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/R
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Chile - HTA Country/Area Profile



	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	Yes	No	Yes	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Mandate from Policy Authority	Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Qualified human resources		Rank 2	Data Availability
	Rank 3	N/R		Rank 3	Knowledge of methods
	Rank 4	N/R		Rank 4	Dedicated human resources
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





China - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Independent committee	Independent committee	Independent committee	Independent committee	Independent committee
Assessment	Research institutes/universities/consulting companies	Research institutes/universities/consulting companies	Research institutes/universities/consulting companies	Research institutes/universities/consulting companies	Research institutes/universities
Recommendation	National healthcare security institutes/National Health Commission	National healthcare security institutes/National Health Commission	National healthcare security institutes/National Health Commission	National healthcare security institutes/National Health Commission	National healthcare security institutes/National Health Commission/Ministry of Finance

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	Yes	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	No	Do you assess impact?	Yes
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





China - HTA Country/Area Profile



Available Resources

Question	Response
How many professional staff (FTE) are involved in the HTA body?	More than 100
Allocated public sector budget?	Yes

Question	Response
Are any resources received through private funding?	N/R
If so, what percentage?	N/R



Assessments

Question	Response
How long does the assessment process take on average?	6-12 months
In the last 12 months, approximately how many assessments were performed?	21



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	N/R
Do you have a database of health technology costs or prices?	N/R
Is there an officially endorsed cost-effectiveness threshold?	N/R
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	No	No	No	No	Yes



Barriers

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



China - HTA Country/Area Profile



Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	N/R	Barriers to Production Capability	Rank 1	N/R
	Rank 2	N/R		Rank 2	N/R
	Rank 3	N/R		Rank 3	N/R
	Rank 4	N/R		Rank 4	N/R
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Colombia - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	IETS	IETS	IETS	IETS	IETS
Assessment	IETS	IETS	IETS	IETS	IETS
Recommendation	IETS	IETS	IETS	IETS	IETS

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	No	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R	Are any resources received through private funding?	N/R
Allocated public sector budget?	No	If so, what percentage?	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Colombia - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	200



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	N/R
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Institutionalization of HTA		Rank 2	N/R
	Rank 3	Mandate from Policy Authority		Rank 3	N/R
	Rank 4	Political support		Rank 4	N/R
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Comoros - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		N/A
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	N/R
	Planning and budgeting	N/R
	Pricing/pricing negotiations of medical technologies	N/R
	Indicators of quality of care	N/R
	Objectives for pay-for-performance schemes	N/R
	Design of Health Benefit Packages	N/R
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	N/R
	Other	Regulation of health products

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	N/R	N/R	N/R	N/R	N/R
Assessment	National drug agency and Comorian Office of Pharmaceutical Products (Ocopharma)	N/R	National drug agency and Comorian Office of Pharmaceutical Products (Ocopharma)	N/R	Comorian Office of Pharmaceutical Products (Ocopharma) and PEV
Recommendation	National drug agency	N/R	National drug agency	N/R	PEV

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	Yes	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	N/R	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	N/R	Do you assess impact?	No
	National Health Service	Yes		
	Patient Organizations	N/R		
	Civil Society	N/R		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Comoros - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20
Allocated public sector budget?	Yes

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	1-3 months
In the last 12 months, approximately how many assessments were performed?	1



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	No



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	Yes	Yes	Yes	N/R	Yes



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Political support	Barriers to Production Capability	Rank 1	Dedicated human resources
	Rank 2	Qualified human resources		Rank 2	Budget availability
	Rank 3	Awareness/Advocacy of the importance of HTA		Rank 3	Knowledge of methods
	Rank 4	N/R		Rank 4	N/R
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Costa Rica - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	No
	Subnational Level	Yes
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		N/A
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		N/R

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Costa Rican social security unit	N/R	Costa Rican social security unit	Costa Rican social security unit	N/R
Assessment	Costa Rican social security unit	N/R	Costa Rican social security unit	Costa Rican social security unit	N/R
Recommendation	Costa Rican social security unit	N/R	Costa Rican social security unit	Costa Rican social security unit	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	No	Do you assess impact?	N/R
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Costa Rica - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R
Allocated public sector budget?	No

Question	Response
Are any resources received through private funding?	N/R
If so, what percentage?	N/R



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	50



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	N/R
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA
	Rank 2	Institutionalization of HTA
	Rank 3	Mandate from Policy Authority
	Rank 4	Qualified human resources
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Data Availability
	Rank 3	Knowledge of methods
	Rank 4	Dedicated human resources
	Rank 5	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Côte d'Ivoire - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	Yes
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		I don't know

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	DAP/AIRP	DIIS	DIEM	LNSP/AIRP	DIIS/DSC
Assessment	DAP/AIRP	DIIS	DIEM	LNSP/AIRP	DIIS/DSC
Recommendation	DGS	DGS	DGS	DGS	DGS

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	N/R
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	More than 100	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	Yes	If so, what percentage?	N/A

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Côte d'Ivoire - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	More than 1 year
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	N/R
Is there an officially endorsed cost-effectiveness threshold?	N/R
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	No	No	No	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Institutionalization of HTA	Barriers to Production Capability	Rank 1	Data Availability
	Rank 2	Awareness/Advocacy of the importance of HTA		Rank 2	Budget availability
	Rank 3	Mandate from Policy Authority		Rank 3	Knowledge of methods
	Rank 4	Political support		Rank 4	Dedicated human resources
	Rank 5	Qualified human resources		Rank 5	Other Issues
	Rank 6	Other Issues			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Croatia - HTA Country/Area Profile¹



Institutions & governance

Question	Response
Has a systematic process to support healthcare decision-making?	No
Please describe your health-care decision making process below.	N/R
Can you indicate whether there are plans for implementing a systematic formal process and if so, what that time-frame is?	N/R
Any prioritization criteria used to determine which health technologies and interventions are considered in government health schemes in the country?	N/R
Is evidence collected for making decisions about the inclusion or exclusion of health technologies and interventions?	N/R
Are there any formal or informal procedures, rules, thresholds, or laws that factor in to the decision-making related to health technologies and interventions?	N/R

Question	Entity	Title/Function	Response
Entities(e.g. organizations/individuals/officials) involved in decisions regarding inclusion or exclusion of health technologies and interventions:	Entity 1	Title of Entity	N/R
		Functions Performed	N/R
	Entity 2	Title of Entity	N/R
		Functions Performed	N/R
	Entity 3	Title of Entity	N/R
		Functions Performed	N/R
	Entity 4	Title of Entity	N/R
		Functions Performed	N/R
	Entity 5	Title of Entity	N/R
		Functions Performed	N/R

Question	Option	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Question	Response
Provisions for revising decisions about health technologies and interventions once they are made.	N/R
Mechanism for translation or contextualization of evidence?	N/R

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Croatia - HTA Country/Area Profile¹



Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Mandate from Policy Authority
	Rank 2	Political support
	Rank 3	Qualified human resources
	Rank 4	N/R
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production capability	Rank 1	Budget availability
	Rank 2	Dedicated human resources
	Rank 3	Knowledge of methods
	Rank 4	N/R
	Rank 5	N/R

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Cuba - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	CECMED	CECMED	CECMED	CECMED	CECMED
Assessment	CECMED	CECMED	CECMED	CECMED	CECMED
Recommendation	EVALUATION COMMITTEE FOR THE INTRODUCTION OF HEALTH TECHNOLOGIES	EVALUATION COMMITTEE FOR THE INTRODUCTION OF HEALTH TECHNOLOGIES	EVALUATION COMMITTEE FOR THE INTRODUCTION OF HEALTH TECHNOLOGIES	EVALUATION COMMITTEE FOR THE INTRODUCTION OF HEALTH TECHNOLOGIES	EVALUATION COMMITTEE FOR THE INTRODUCTION OF HEALTH TECHNOLOGIES

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R
	Department/Ministry of Health	No	Do you assess impact?	Yes
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Cuba - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R
Allocated public sector budget?	Yes

Question	Response
Are any resources received through private funding?	N/R
If so, what percentage?	N/R



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	35



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	N/R
Is there an officially endorsed cost-effectiveness threshold?	N/R
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	No



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/R
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	N/R
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	N/R
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Cyprus - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Health Insurance Organization	N/R	Ministry of Health	Ministry of Health	N/R
Assessment	Health Insurance Organization	N/R	Ministry of Health	Ministry of Health	N/R
Recommendation	Health Insurance Organization	N/R	Ministry of Health	Ministry of Health	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	No	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Cyprus - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20
Allocated public sector budget?	No

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	Yes
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	Yes



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Political support
	Rank 2	Awareness/Advocacy of the importance of HTA
	Rank 3	Mandate from Policy Authority
	Rank 4	Institutionalization of HTA
	Rank 5	Qualified human resources
	Rank 6	Other Issues

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Data Availability
	Rank 2	Budget availability
	Rank 3	Knowledge of methods
	Rank 4	Dedicated human resources
	Rank 5	Other Issues

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Czech Republic - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	SUKL	Ministry of Health	Ministry of Health	N/R	Ministry of Health
Assessment	SUKL	Ministry of Health	SUKL	N/R	Ministry of Health
Recommendation	SUKL	Ministry of Health	Ministry of Health	N/R	Ministry of Health

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	No	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	21 to 50	Are any resources received through private funding?	Yes
Allocated public sector budget?	Yes	If so, what percentage?	25

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Czech Republic - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	6-12 months
In the last 12 months, approximately how many assessments were performed?	45



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	Yes
If so, what is it?	46 000 EUR/QALY
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	N/R
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	N/R
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R
	Rank 6	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Democratic Republic of the Congo - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	Yes
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	N/R	N/R	N/R	N/R	N/R
Assessment	N/R	N/R	N/R	N/R	N/R
Recommendation	N/R	N/R	N/R	N/R	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	Yes
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20	Are any resources received through private funding?	Yes
Allocated public sector budget?	No	If so, what percentage?	17

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Democratic Republic of the Congo - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	1-3 months
In the last 12 months, approximately how many assessments were performed?	5



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	Yes
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	Yes	Yes	Yes	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Political support
	Rank 2	Awareness/Advocacy of the importance of HTA
	Rank 3	Institutionalization of HTA
	Rank 4	Qualified human resources
	Rank 5	Mandate from Policy Authority
	Rank 6	Other Issues

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Dedicated human resources
	Rank 3	Knowledge of methods
	Rank 4	Data Availability
	Rank 5	Other Issues

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Dominican Republic - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		N/R
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	General Directorate of Medicines, Food and Health Products / SUPERINTENDENCY OF HEALTH AND LABOR RISKS / HFG / USAID INTERNATIONAL CONSULTANCY	N/R	N/R	N/R	N/R
Assessment	General Directorate of Medicines, Food and Health Products / SUPERINTENDENCY OF HEALTH AND LABOR RISKS / HFG / USAID INTERNATIONAL CONSULTANCY	N/R	N/R	N/R	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Dominican Republic - HTA Country/Area Profile



Recommendation	General Directorate of Medicines, Food and Health Products / SUPERINTENDENCY OF HEALTH AND LABOR RISKS / HFG / USAID INTERNATIONAL CONSULTANCY	N/R	N/R	N/R	N/R
----------------	--	-----	-----	-----	-----

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R
	Department/Ministry of Health	Yes	Do you assess impact?	N/R
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R	Are any resources received through private funding?	N/R
Allocated public sector budget?	Yes	If so, what percentage?	N/R



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	N/R
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Question						Response
Is there a possibility to appeal against the decision?						N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?						No
	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA
	Rank 2	Institutionalization of HTA
	Rank 3	Mandate from Policy Authority
	Rank 4	Qualified human resources
	Rank 5	N/R
	Rank 6	N/R

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

 World Health Organization



Ecuador - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	National Directorate of Health Intelligence	National Directorate of Health Intelligence	National Directorate of Health Intelligence	National Directorate of Health Intelligence	National Directorate of Health Intelligence
Assessment	National Directorate of Health Intelligence	National Directorate of Health Intelligence	National Directorate of Health Intelligence	National Directorate of Health Intelligence	National Directorate of Health Intelligence
Recommendation	National Directorate of Health Intelligence	National Directorate of Health Intelligence	National Directorate of Health Intelligence	National Directorate of Health Intelligence	National Directorate of Health Intelligence

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R
	Department/Ministry of Health	No	Do you assess impact?	N/R
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Ecuador - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R
Allocated public sector budget?	No

Question	Response
Are any resources received through private funding?	N/R
If so, what percentage?	N/R



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	52



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA
	Rank 2	Institutionalization of HTA
	Rank 3	Mandate from Policy Authority
	Rank 4	Political support
	Rank 5	Qualified human resources
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Data Availability
	Rank 3	Knowledge of methods
	Rank 4	Dedicated human resources
	Rank 5	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



El Salvador - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	N/R	N/R	N/R	N/R	N/R
Assessment	N/R	N/R	N/R	N/R	N/R
Recommendation	N/R	N/R	N/R	N/R	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R
	Department/Ministry of Health	No	Do you assess impact?	N/R
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R	Are any resources received through private funding?	N/R
Allocated public sector budget?	No	If so, what percentage?	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





El Salvador - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	7



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	N/R
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Institutionalization of HTA		Rank 2	Data Availability
	Rank 3	Mandate from Policy Authority		Rank 3	Knowledge of methods
	Rank 4	Political support		Rank 4	Dedicated human resources
	Rank 5	Other Issues		Rank 5	N/R
	Rank 6	Qualified human resources			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Eritrea - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	Yes
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		N/A
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	No
	Other	performance of the health system and service delivery activities, pharmacovigilance and postmarket surveillance

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	National Medicines and Therapeutic Committee	N/R	Medical Registration Committee	Medical Registration Committee	NITAG
Assessment	National Medicine and Food Administration	Medical Services Department	National Medicine and Food Administration	National Medicine and Food Administration	National Medicine and Food Administration
Recommendation	National Medicine and Food Administration	N/R	National Medicine and Food Administration	National Medicine and Food Administration	Ministry of Health

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Eritrea - HTA Country/Area Profile



Available Resources

Question	Response
How many professional staff (FTE) are involved in the HTA body?	1 to 5
Allocated public sector budget?	Yes

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	3-6 months
In the last 12 months, approximately how many assessments were performed?	23



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Eritrea - HTA Country/Area Profile



Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Institutionalization of HTA	Barriers to Production Capability	Rank 1	Dedicated human resources
	Rank 2	Awareness/Advocacy of the importance of HTA		Rank 2	Knowledge of methods
	Rank 3	Qualified human resources		Rank 3	Data Availability
	Rank 4	Political support		Rank 4	Budget availability
	Rank 5	Mandate from Policy Authority		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Eswatini - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	Yes
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Pharmacovigilant Unit	Ministry of Health	NGOs	Radiography Unit	Expanded Programme of Immunization
Assessment	Central Medical Stores	Deputy Director Pharmaceutical	Occupational Therapy Unit Mbabane Govt Hospital	National Referral Laboratory	General Population
Recommendation	Medicines Regulatory Authority	Medicines Regulatory Authority	Ministry of Health	Ministry of Health	NITAG

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	Yes	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	Yes
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	Yes		

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Eswatini - HTA Country/Area Profile



Available Resources

Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20
Allocated public sector budget?	I don't know

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	3-6 months
In the last 12 months, approximately how many assessments were performed?	6



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	N/R
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	No



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	Yes	No	Yes	No	No



Barriers

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Eswatini - HTA Country/Area Profile



Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Institutionalization of HTA	Barriers to Production Capability	Rank 1	Knowledge of methods
	Rank 2	Awareness/Advocacy of the importance of HTA		Rank 2	Budget availability
	Rank 3	Political support		Rank 3	Dedicated human resources
	Rank 4	Qualified human resources		Rank 4	Data Availability
	Rank 5	Mandate from Policy Authority		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Ethiopia - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	1. Food, Medicine and Health Care Administration and Control Authority 2. Ethiopia Public Health Institutions 3. Ministry of Health 4. Ethiopian Food and Drug Administration 5. Ethiopia Health insurance agency	Ministry of Health-Clinical Directorate	Ethiopian Pharmaceutical Supply Agency (EPSA)	EPHI/MoH	Ministry of Health and respective Agency
Assessment	1. Food, Medicine and Health Care Administration and Control Authority 2. Ethiopia Public Health Institutions	Health Facilities	Ethiopian Pharmaceutical Supply Agency (EPSA)	Health Facilities/EPHI	Ministry of Health and respective Agency

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Ethiopia - HTA Country/Area Profile



Recommendation	1. Food, Medicine and Health Care Administration and Control Authority 2. Ethiopia Public Health Institutions 3. Ministry of Health 4. Ethiopian Food and Drug Administration 5. Ethiopia Health insurance agency	Ministry of Health-Clinical Directorate	Ethiopian Pharmaceutical Supply Agency (EPSA) and MoH	EPHI/MoH	Ministry of Health and respective Agency
-----------------------	---	---	---	----------	--

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	1 to 5	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	Yes	If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	3-6 months
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Ethiopia - HTA Country/Area Profile



Question	Response
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/R
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	Yes	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Data Availability
	Rank 2	Institutionalization of HTA		Rank 2	Budget availability
	Rank 3	Qualified human resources		Rank 3	Dedicated human resources
	Rank 4	Mandate from Policy Authority		Rank 4	Knowledge of methods
	Rank 5	Political support		Rank 5	Other Issues
	Rank 6	Other Issues			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



France - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	HAS	HAS	HAS	HAS	HAS
Assessment	HAS	HAS	HAS	HAS	HAS
Recommendation	Ministries	Ministries	Ministries	Ministries	Ministries

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	Yes	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	Yes
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	51 to 100	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	Yes	If so, what percentage?	N/A

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





France - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	1-3 months
In the last 12 months, approximately how many assessments were performed?	942



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	Yes	No	Yes	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	N/R
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Dedicated human resources
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Gabon - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	Yes
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	Yes
	Other	Epidemiological data

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	DMP / OPM (Central purchasing office)	SG / Cabinet of the Minister / General Directorate of Health Services	DMP / OPM (Central purchasing office)	DMP / OPM (Central Purchasing) / National Blood Transfusion Center	DMP / OPM (Central Purchasing) / National Blood Transfusion Center
Assessment	DMP / OPM (Central purchasing office)	SG / Cabinet of the Minister / General Directorate of Health Services	DMP / OPM (Central purchasing office)	DMP / OPM (Central Purchasing) / National Blood Transfusion Center	DMP / OPM (Central Purchasing) / National Blood Transfusion Center
Recommendation	SG / Cabinet of the Minister / DMP / OPM (Central purchasing office)	SG / Cabinet of the Minister / General Directorate of Health Services	SG / Cabinet of the Minister / DMP / OPM (Central purchasing office)	SG / Cabinet of the Minister / DMP / OPM (Central purchasing office)	SG / Cabinet of the Minister / DMP / OPM (Central purchasing office)

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Gabon - HTA Country/Area Profile



Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	Yes
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	Yes		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	21 to 50	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	Yes	If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	3-6 months
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	N/R
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Gabon - HTA Country/Area Profile



	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Data Availability
	Rank 2	Institutionalization of HTA		Rank 2	Dedicated human resources
	Rank 3	Qualified human resources		Rank 3	Budget availability
	Rank 4	Mandate from Policy Authority		Rank 4	Knowledge of methods
	Rank 5	Other Issues		Rank 5	Other Issues
	Rank 6	Political support			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Gambia - HTA Country/Area Profile¹



Institutions & governance

Question	Response
Has a systematic process to support healthcare decision-making?	No
Please describe your health-care decision making process below.	Cabinet decisions through cabinet papers are implemented by the Ministry of health
Can you indicate whether there are plans for implementing a systematic formal process and if so, what that time-frame is?	There is no plan to implement such a process
Any prioritization criteria used to determine which health technologies and interventions are considered in government health schemes in the country?	No
Is evidence collected for making decisions about the inclusion or exclusion of health technologies and interventions?	N/R
Are there any formal or informal procedures, rules, thresholds, or laws that factor in to the decision-making related to health technologies and interventions?	Yes

Question	Entity	Title/Function	Response
Entities(e.g. organizations/individuals/officials) involved in decisions regarding inclusion or exclusion of health technologies and interventions:	Entity 1	Title of Entity	N/R
		Functions Performed	N/R
	Entity 2	Title of Entity	N/R
		Functions Performed	N/R
	Entity 3	Title of Entity	N/R
		Functions Performed	N/R
	Entity 4	Title of Entity	N/R
		Functions Performed	N/R
	Entity 5	Title of Entity	N/R
		Functions Performed	N/R

Question	Option	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	No
	Other	N/R

Question	Response
Provisions for revising decisions about health technologies and interventions once they are made.	N/R
Mechanism for translation or contextualization of evidence?	No

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Gambia - HTA Country/Area Profile¹



Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Institutionalization of HTA	Barriers to Production capability	Rank 1	Data Availability
	Rank 2	Political support		Rank 2	Budget availability
	Rank 3	N/R		Rank 3	Other Issues
	Rank 4	N/R		Rank 4	N/R
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Germany - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	G-BA	G-BA	G-BA	G-BA	G-BA
Assessment	IQWiG, G-BA	IQWiG, G-BA	IQWiG, G-BA	IQWiG, G-BA	IQWiG, G-BA
Recommendation	G-BA	G-BA	G-BA	G-BA	G-BA

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	No	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	Yes		
	Civil Society	No		
	Other	Yes		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	More than 100	Are any resources received through private funding?	Yes
Allocated public sector budget?	Yes	If so, what percentage?	5

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Germany - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	6-12 months
In the last 12 months, approximately how many assessments were performed?	100



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	N/R
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	No	Yes	Yes	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Political support
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Dedicated human resources
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Ghana - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Appraisal SubGroup - HTA Technical Working Group	Appraisal SubGroup - HTA Technical Working Group	Appraisal SubGroup - HTA Technical Working Group	Appraisal SubGroup - HTA Technical Working Group	Appraisal SubGroup - HTA Technical Working Group
Assessment	Analysis SubGroup - HTA Technical Working Group	Analysis SubGroup - HTA Technical Working Group	Analysis SubGroup - HTA Technical Working Group	Analysis SubGroup - HTA Technical Working Group	Analysis SubGroup - HTA Technical Working Group
Recommendation	HTA Steering Committee	HTA Steering Committee	HTA Steering Committee	HTA Steering Committee	HTA Steering Committee

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	Yes	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Ghana - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	1 to 5
Allocated public sector budget?	No

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	3-6 months
In the last 12 months, approximately how many assessments were performed?	1



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	Yes
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	Yes	Yes	Yes	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Mandate from Policy Authority	Barriers to Production Capability	Rank 1	Knowledge of methods
	Rank 2	N/R		Rank 2	Budget availability
	Rank 3	N/R		Rank 3	Data Availability
	Rank 4	N/R		Rank 4	N/R
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Greece - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	HTA committee	N/R	N/R	N/R	N/R
Assessment	HTA committee	N/R	N/R	N/R	N/R
Recommendation	HTA committee	N/R	N/R	N/R	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	Yes	If so, what percentage?	N/A

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Greece - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	3-6 months
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	Yes	Yes	Yes	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Data Availability
	Rank 2	Qualified human resources		Rank 2	Budget availability
	Rank 3	Other Issues		Rank 3	Dedicated human resources
	Rank 4	N/R		Rank 4	N/R
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Guyana - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		N/A
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		N/R

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	N/R	N/R	N/R	N/R	N/R
Assessment	N/R	N/R	N/R	N/R	N/R
Recommendation	N/R	N/R	N/R	N/R	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R
	Department/Ministry of Health	No	Do you assess impact?	N/R
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R	Are any resources received through private funding?	N/R
Allocated public sector budget?	N/R	If so, what percentage?	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Guyana - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	N/R
Is there an officially endorsed cost-effectiveness threshold?	N/R
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	N/R
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	N/R
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Honduras - HTA Country/Area Profile¹



Institutions & governance

Question	Response
Has a systematic process to support healthcare decision-making?	No
Please describe your health-care decision making process below.	N/R
Can you indicate whether there are plans for implementing a systematic formal process and if so, what that time-frame is?	There will be a process in place in 3-5 years
Any prioritization criteria used to determine which health technologies and interventions are considered in government health schemes in the country?	N/R
Is evidence collected for making decisions about the inclusion or exclusion of health technologies and interventions?	No
Are there any formal or informal procedures, rules, thresholds, or laws that factor in to the decision-making related to health technologies and interventions?	No

Question	Entity	Title/Function	Response
Entities(e.g. organizations/individuals/officials) involved in decisions regarding inclusion or exclusion of health technologies and interventions:	Entity 1	Title of Entity	N/R
		Functions Performed	N/R
	Entity 2	Title of Entity	N/R
		Functions Performed	N/R
	Entity 3	Title of Entity	N/R
		Functions Performed	N/R
	Entity 4	Title of Entity	N/R
		Functions Performed	N/R
	Entity 5	Title of Entity	N/R
		Functions Performed	N/R

Question	Option	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Question	Response
Provisions for revising decisions about health technologies and interventions once they are made.	N/R
Mechanism for translation or contextualization of evidence?	No

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Honduras - HTA Country/Area Profile¹



Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA
	Rank 2	Institutionalization of HTA
	Rank 3	Political support
	Rank 4	Qualified human resources
	Rank 5	Mandate from Policy Authority
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production capability	Rank 1	Budget availability
	Rank 2	Data Availability
	Rank 3	Knowledge of methods
	Rank 4	Dedicated human resources
	Rank 5	N/R

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Hungary - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	international HTA agencies

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	TÉB-committee	TÉB-committee	TÉB-committee	TÉB-committee	N/R
Assessment	OGYÉI and scientific committee	OGYÉI and scientific committee	OGYÉI and scientific committee	OGYÉI and scientific committee	N/R
Recommendation	NEAK-payer and Ministry of Health	NEAK and Ministry of Health (EMMI)	NEAK and Ministry of Health (EMMI)	NEAK and Ministry of Health (EMMI)	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	Yes	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	Yes		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Hungary - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20
Allocated public sector budget?	Yes

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	1-3 months
In the last 12 months, approximately how many assessments were performed?	271



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	Yes
If so, what is it?	The cost-effectiveness threshold is three times the GDP per capita.
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	No
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	No	No	Yes	No	No



Barriers

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Hungary - HTA Country/Area Profile



Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Data Availability
	Rank 2	Qualified human resources		Rank 2	Budget availability
	Rank 3	Institutionalization of HTA		Rank 3	Knowledge of methods
	Rank 4	Mandate from Policy Authority		Rank 4	Dedicated human resources
	Rank 5	Political support		Rank 5	Other Issues
	Rank 6	Other Issues			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Iceland - HTA Country/Area Profile¹



Institutions & governance

Question	Response
Has a systematic process to support healthcare decision-making?	No
Please describe your health-care decision making process below.	Healthcare systems, no matter how well they are structured, cannot play their role without an efficient managerial system and managers with sound leadership qualities. The legislature and the executive are involved in deciding how the health services are organised; they define their role, monitor to ensure that the system meets public expectations and see to it that funding is spent on the most urgently needed services. In addition, the legislature and the executive must ensure that the necessary demands are made regarding staff education and skills, that the necessary quality standards are demanded of institutions providing health services and that the need for new equipment and medicines is assessed (HTA – Health Technology Assessment). See: https://www.government.is/library/01-Ministries/Ministry-of-Health/PDF-skjol/Heilbrigdisstefna_english.pdf
Can you indicate whether there are plans for implementing a systematic formal process and if so, what that time-frame is?	There will be a process in place in 1-2 years
Any prioritization criteria used to determine which health technologies and interventions are considered in government health schemes in the country?	No
Is evidence collected for making decisions about the inclusion or exclusion of health technologies and interventions?	No
Are there any formal or informal procedures, rules, thresholds, or laws that factor in to the decision-making related to health technologies and interventions?	N/R

Question	Entity	Title/Function	Response
Entities(e.g. organizations/individuals/officials) involved in decisions regarding inclusion or exclusion of health technologies and interventions:	Entity 1	Title of Entity	Directorate of Health
		Functions Performed	https://www.landlaeknir.is/english/
	Entity 2	Title of Entity	Icelandic Medicines Agency
		Functions Performed	https://www.ima.is/
	Entity 3	Title of Entity	N/R
		Functions Performed	N/R
	Entity 4	Title of Entity	N/R
		Functions Performed	N/R
	Entity 5	Title of Entity	N/R
		Functions Performed	N/R

Question	Option	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	No

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Iceland - HTA Country/Area Profile¹



Functions for which decision-making information is gathered?	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Question	Response
Provisions for revising decisions about health technologies and interventions once they are made.	N/R
Mechanism for translation or contextualization of evidence?	No
Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA
	Rank 2	Qualified human resources
	Rank 3	Institutionalization of HTA
	Rank 4	Other Issues
	Rank 5	Political support
	Rank 6	Mandate from Policy Authority

Question	Ranking	Response
Barriers to Production capability	Rank 1	Budget availability
	Rank 2	Data Availability
	Rank 3	Knowledge of methods
	Rank 4	Dedicated human resources
	Rank 5	Other Issues

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



India - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		N/R

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	N/R	N/R	N/R	N/R	N/R
Assessment	N/R	N/R	N/R	N/R	N/R
Recommendation	N/R	N/R	N/R	N/R	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	Yes	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	Yes
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	Yes	If so, what percentage?	N/A

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





India - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	3-6 months
In the last 12 months, approximately how many assessments were performed?	7



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	Yes
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	Yes	No	No	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Institutionalization of HTA
	Rank 2	Awareness/Advocacy of the importance of HTA
	Rank 3	Mandate from Policy Authority
	Rank 4	N/R
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Data Availability
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Indonesia - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	*Provide policy recommendation of health benefit packages to the Minister of Health. *Conducting assessment and appraisal of health technologies

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Indonesia HTA Committee (InaHTAC) and adhoc panel	Indonesia HTA Committee (InaHTAC) and adhoc panel	N/R	N/R	N/R
Assessment	HTA agent from Ministry of Health and Universities	HTA agent from Ministry of Health and Universities	N/R	N/R	N/R
Recommendation	Indonesia HTA Committee (InaHTAC)	Indonesia HTA Committee (InaHTAC)	N/R	N/R	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Indonesia - HTA Country/Area Profile



Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	No	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	Yes		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	1 to 5	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	Yes	If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	6-12 months
In the last 12 months, approximately how many assessments were performed?	4



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	Yes
If so, what is it?	The cost-effectiveness threshold using a range of 1-3 Indonesia's GDP. The threshold has been used since 2015 until now.
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	Yes
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Indonesia - HTA Country/Area Profile



	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	No	No	Yes	Yes	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Qualified human resources	Barriers to Production Capability	Rank 1	Data Availability
	Rank 2	Institutionalization of HTA		Rank 2	Budget availability
	Rank 3	Awareness/Advocacy of the importance of HTA		Rank 3	Dedicated human resources
	Rank 4	Political support		Rank 4	Knowledge of methods
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Iran (Islamic Republic of) - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Deputy for Curative Affairs - Iran (Islamic Republic of) FDA - National Institute for Health Research	Deputy for Curative Affairs - National Institute for Health Research	Deputy for Curative Affairs - Iran (Islamic Republic of) FDA - National Institute for Health Research	Deputy for Curative Affairs - National Institute for Health Research	Deputy for Curative Affairs - National Institute for Health Research
Assessment	Deputy for Curative Affairs - Universities of Medical Sciences - Iran (Islamic Republic of) FDA - National Institute for Health Research	Deputy for Curative Affairs - Universities of Medical Sciences - National Institute for Health Research	Deputy for Curative Affairs - Universities of Medical Sciences - Iran (Islamic Republic of) FDA - National Institute for Health Research	Deputy for Curative Affairs - Universities of Medical Sciences - National Institute for Health Research	Deputy for Curative Affairs - Universities of Medical Sciences - National Institute for Health Research
Recommendation	Deputy for Curative Affairs - High Council for Health Insurances - Iran (Islamic Republic of) FDA	Deputy for Curative Affairs - High Council for Health Insurances	Deputy for Curative Affairs - High Council for Health Insurances - Iran (Islamic Republic of) FDA	Deputy for Curative Affairs - High Council for Health Insurances	Deputy for Curative Affairs - High Council for Health Insurances

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Iran (Islamic Republic of) - HTA Country/Area Profile



Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	Yes	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	Yes
	National Health Service	Yes		
	Patient Organizations	N/R		
	Civil Society	N/R		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	Yes	If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	3-6 months
In the last 12 months, approximately how many assessments were performed?	24



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	Yes
If so, what is it?	It is equal to one GDP announced from the Central Bank of Iran (Islamic Republic of) yearly. It has been started since 2016.
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	Yes
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Iran (Islamic Republic of) - HTA Country/Area Profile



	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	N/R	N/R	Yes	N/R	N/R



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Political support	Barriers to Production Capability	Rank 1	Data Availability
	Rank 2	Qualified human resources		Rank 2	Dedicated human resources
	Rank 3	Institutionalization of HTA		Rank 3	Budget availability
	Rank 4	Mandate from Policy Authority		Rank 4	Knowledge of methods
	Rank 5	Awareness/Advocacy of the importance of HTA		Rank 5	Other Issues
	Rank 6	Other Issues			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Ireland - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	Yes
	Other	Decision to introduce a new programme e.g. new surgical technique

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	National Centre for Pharmacoeconomics	HIQA	HIQA	HIQA	HIQA
Assessment	National Centre for Pharmacoeconomics	HIQA	HIQA	HIQA	HIQA
Recommendation	National Centre for Pharmacoeconomics	HIQA	HIQA	HIQA	HIQA

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Ireland - HTA Country/Area Profile



Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	Yes
	National Health Service	Yes		
	Patient Organizations	Yes		
	Civil Society	No		
	Other	Yes		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	Yes	If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	6-12 months
In the last 12 months, approximately how many assessments were performed?	3



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	Yes
If so, what is it?	€20,000/QALY and €45,000/QALY Since approximately 2000 and have never been reviewed
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	No
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Ireland - HTA Country/Area Profile



	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Mandate from Policy Authority	Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Awareness/Advocacy of the importance of HTA		Rank 2	Dedicated human resources
	Rank 3	Institutionalization of HTA		Rank 3	Data Availability
	Rank 4	Qualified human resources		Rank 4	N/R
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Italy - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	Medicine reimbursement decisions

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	AIFA	N/R	N/R	N/R	N/R
Assessment	AIFA	N/R	N/R	N/R	N/R
Recommendation	AIFA	N/R	N/R	N/R	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	Yes	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
	Director of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R
	Department/Ministry of Health	No	Do you assess impact?	Yes
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	Yes		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Italy - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	21 to 50
Allocated public sector budget?	Yes

Question	Response
Are any resources received through private funding?	Yes
If so, what percentage?	N/R



Assessments

Question	Response
How long does the assessment process take on average?	1-3 months
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/R
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	No	No	Yes	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Qualified human resources
	Rank 2	Institutionalization of HTA
	Rank 3	Awareness/Advocacy of the importance of HTA
	Rank 4	Mandate from Policy Authority
	Rank 5	Political support
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Dedicated human resources
	Rank 2	Knowledge of methods
	Rank 3	Data Availability
	Rank 4	Budget availability
	Rank 5	Other Issues

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Jamaica - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	Yes
Do you refer to this as HTA?		N/R
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		N/R

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	N/R	N/R	N/R	N/R	N/R
Assessment	N/R	N/R	N/R	N/R	N/R
Recommendation	N/R	N/R	N/R	N/R	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R
	Department/Ministry of Health	No	Do you assess impact?	N/R
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R	Are any resources received through private funding?	N/R
Allocated public sector budget?	N/R	If so, what percentage?	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Jamaica - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	N/R
Do you have a database of health technology costs or prices?	N/R
Is there an officially endorsed cost-effectiveness threshold?	N/R
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	N/R
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	N/R
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R
	Rank 6	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Japan - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Expert Committee on Cost-Effectiveness Evaluation at the Central Social Insurance Medical Council	N/R	Expert Committee on Cost-Effectiveness Evaluation at the Central Social Insurance Medical Council	N/R	N/R
Assessment	Center for Outcomes Research and Economic Evaluation for Health (C2H) in the National Institute of Public Health	N/R	Center for Outcomes Research and Economic Evaluation for Health (C2H) in the National Institute of Public Health	N/R	N/R
Recommendation	Central Social Insurance Medical Council	N/R	Central Social Insurance Medical Council	N/R	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Japan - HTA Country/Area Profile



Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	No	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	Yes		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	Yes	If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	More than 1 year
In the last 12 months, approximately how many assessments were performed?	10



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	Yes

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Japan - HTA Country/Area Profile



Question	Response
If so, what is it?	The results of cost effectiveness analysis are used for price adjustment. Because we do not deny the products based on their cost effectiveness, we do not use the word "threshold" but use "reference value". If the result exceeds the reference values, price will be adjusted. The price will be lowered by 3 steps, when the incremental cost effectiveness ratio (ICER) exceeds 5 million JPY per QALY, 7.5 million JPY per QALY, 10 million JPY per QALY. In the case of oncology, pediatric, and designated intractable and rare disease products, these reference values are increased by a factor of 1.5, which means 7.5 million JPY per QALY, 11.25 million JPY per QALY, and 15 million JPY per QALY. This system started in April 2019. These reference values are used from the beginning and have never reviewed yet.
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question						Response
Is there a possibility to appeal against the decision?						No
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?						Yes
	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	Yes	No	Yes	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Qualified human resources	Barriers to Production Capability	Rank 1	Dedicated human resources
	Rank 2	Other Issues		Rank 2	Data Availability
	Rank 3	N/R		Rank 3	N/R
	Rank 4	N/R		Rank 4	N/R
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Kenya - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	Yes
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	N/R	N/R	N/R	N/R	N/R
Assessment	N/R	N/R	N/R	N/R	N/R
Recommendation	N/R	N/R	N/R	N/R	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	Yes	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	No	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	1 to 5	Are any resources received through private funding?	Yes
Allocated public sector budget?	No	If so, what percentage?	5

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Kenya - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Institutionalization of HTA	Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Awareness/Advocacy of the importance of HTA		Rank 2	Dedicated human resources
	Rank 3	Qualified human resources		Rank 3	Knowledge of methods
	Rank 4	N/R		Rank 4	Data Availability
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Kuwait - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		N/A
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		I don't know

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	N/R	N/R	N/R	N/R	Public Health Sector
Assessment	Central Medical Stores	Medical departments	Medical Engineering Administration	Central Medical Stores	Public Health Sector
Recommendation	N/R	N/R	N/R	N/R	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Kuwait - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20
Allocated public sector budget?	N/R

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	N/R
Do you have a database of health technology costs or prices?	N/R
Is there an officially endorsed cost-effectiveness threshold?	N/R
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/R
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	N/R
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	N/R
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Kyrgyzstan - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Department of Pharmaceutical Provision and Medical Technologies	N/R	Department of Pharmaceutical Provision and Medical Technologies	Department of Medicines and Medical Technologies	N/R
Assessment	Department of Pharmaceutical Provision and Medical Technologies	N/R	Department of Pharmaceutical Provision and Medical Technologies	Department of Pharmaceutical Provision and Medical Technologies	N/R
Recommendation	Ministry of Health of the Kyrgyz Republic	N/R	Ministry of Health of the Kyrgyz Republic	N/R	The republican center for immunization. Department of Disease Prevention and State Sanitary and Epidemiological Surveillance (SSES MH KR)

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Kyrgyzstan - HTA Country/Area Profile



Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	Yes	If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	No



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	Yes
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Kyrgyzstan - HTA Country/Area Profile



	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	No	No	Yes	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Knowledge of methods
	Rank 2	Political support		Rank 2	Dedicated human resources
	Rank 3	Qualified human resources		Rank 3	Data Availability
	Rank 4	Institutionalization of HTA		Rank 4	Budget availability
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Lao People's Democratic Republic - HTA Country/Area Profile¹



Institutions & governance

Question	Response
Has a systematic process to support healthcare decision-making?	No
Please describe your health-care decision making process below.	There is a system formal Process at the National and subnational level for procurement of Medicine and Medical Products for public sector.
Can you indicate whether there are plans for implementing a systematic formal process and if so, what that time-frame is?	There is no plan to implement such a process
Any prioritization criteria used to determine which health technologies and interventions are considered in government health schemes in the country?	Yes
Is evidence collected for making decisions about the inclusion or exclusion of health technologies and interventions?	Yes
Are there any formal or informal procedures, rules, thresholds, or laws that factor in to the decision-making related to health technologies and interventions?	Yes

Question	Entity	Title/Function	Response
Entities(e.g. organizations/individuals/officials) involved in decisions regarding inclusion or exclusion of health technologies and interventions:	Entity 1	Title of Entity	MOH Procurement Committee
		Functions Performed	Procurement Sector
	Entity 2	Title of Entity	MPSC
		Functions Performed	logistic sector
	Entity 3	Title of Entity	N/R
		Functions Performed	N/R
	Entity 4	Title of Entity	N/R
		Functions Performed	N/R
	Entity 5	Title of Entity	N/R
		Functions Performed	N/R

Question	Option	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Question	Response
Provisions for revising decisions about health technologies and interventions once they are made.	No

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Lao People's Democratic Republic - HTA Country/Area Profile¹



Mechanism for translation or contextualization of evidence?	No
Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA
	Rank 2	Mandate from Policy Authority
	Rank 3	Institutionalization of HTA
	Rank 4	Qualified human resources
	Rank 5	Political support
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production capability	Rank 1	Dedicated human resources
	Rank 2	Knowledge of methods
	Rank 3	Budget availability
	Rank 4	Data Availability
	Rank 5	N/R

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Latvia - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	N/R
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	N/R
	Objectives for pay-for-performance schemes	N/R
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	N/R
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	State Agency of Medicines	N/R	N/R	N/R	N/R
Assessment	State Agency of Medicines	N/R	N/R	N/R	N/R
Recommendation	State Agency of Medicines/ National Health Service	N/R	N/R	N/R	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	N/R	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	N/R	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	N/R	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	N/R	Do you assess impact?	No
	National Health Service	N/R		
	Patient Organizations	N/R		
	Civil Society	N/R		
	Other	Yes		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Latvia - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	1 to 5
Allocated public sector budget?	Yes

Question	Response
Are any resources received through private funding?	Yes
If so, what percentage?	53



Assessments

Question	Response
How long does the assessment process take on average?	3-6 months
In the last 12 months, approximately how many assessments were performed?	34



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	Yes
If so, what is it?	Since August 15, 2018: 3x GDP per capita at current prices in the last year available
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	Yes
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	N/R	N/R	Yes	N/R	N/R



Barriers

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Latvia - HTA Country/Area Profile



Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Qualified human resources	Barriers to Production Capability	Rank 1	Dedicated human resources
	Rank 2	Mandate from Policy Authority		Rank 2	Knowledge of methods
	Rank 3	Institutionalization of HTA		Rank 3	Budget availability
	Rank 4	Awareness/Advocacy of the importance of HTA		Rank 4	Data Availability
	Rank 5	Political support		Rank 5	Other Issues
	Rank 6	Other Issues			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Lebanon - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		N/R
Existence of standard methodology or process guideline?		N/A
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		N/R

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Pharmacy Department	N/R	Health Engineering Department and Projects and Programs Department	N/R	N/R
Assessment	Pharmacy Department	Medical Care Directorate	Health Engineering Department and Projects and Programs Department	Medical Care Directorate	Social health clinic
Recommendation	N/R	N/R	N/R	N/R	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Lebanon - HTA Country/Area Profile



Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	Yes	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	No	Do you assess impact?	N/R
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	1 to 5	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	No	If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	1-3 months
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	N/R
Do you have a database of health technology costs or prices?	N/R
Is there an officially endorsed cost-effectiveness threshold?	N/R
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Lebanon - HTA Country/Area Profile



	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	Yes



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Mandate from Policy Authority		Rank 2	Data Availability
	Rank 3	Qualified human resources		Rank 3	N/R
	Rank 4	Institutionalization of HTA		Rank 4	N/R
	Rank 5	Political support		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Liberia - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	Yes
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Ministry of Health and Liberia Medical & Dental Council	Ministry of Health and Liberia Medicines and Health Products Regulatory Authority	Ministry of Health	Ministry of Health	Ministry of Health
Assessment	Ministry of Health and Liberia Medical & Dental Council	Ministry of Health and Liberia Medicines and Health Products Regulatory Authority	Ministry of Health	Ministry of Health	Ministry of Health
Recommendation	N/R	N/R	N/R	N/R	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Liberia - HTA Country/Area Profile



Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	Yes
	National Health Service	Yes		
	Patient Organizations	No		
	Civil Society	Yes		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	No	If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	7



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Liberia - HTA Country/Area Profile



	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	Yes



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Mandate from Policy Authority	Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Institutionalization of HTA		Rank 2	Data Availability
	Rank 3	Qualified human resources		Rank 3	Knowledge of methods
	Rank 4	Political support		Rank 4	Dedicated human resources
	Rank 5	Awareness/Advocacy of the importance of HTA		Rank 5	Other Issues
	Rank 6	Other Issues			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Libya - HTA Country/Area Profile¹



Institutions & governance

Question	Response
Has a systematic process to support healthcare decision-making?	No
Please describe your health-care decision making process below.	Through regular meetings
Can you indicate whether there are plans for implementing a systematic formal process and if so, what that time-frame is?	There is no plan to implement such a process
Any prioritization criteria used to determine which health technologies and interventions are considered in government health schemes in the country?	N/R
Is evidence collected for making decisions about the inclusion or exclusion of health technologies and interventions?	N/R
Are there any formal or informal procedures, rules, thresholds, or laws that factor in to the decision-making related to health technologies and interventions?	N/R

Question	Entity	Title/Function	Response
Entities(e.g. organizations/individuals/officials) involved in decisions regarding inclusion or exclusion of health technologies and interventions:	Entity 1	Title of Entity	N/R
		Functions Performed	N/R
	Entity 2	Title of Entity	N/R
		Functions Performed	N/R
	Entity 3	Title of Entity	N/R
		Functions Performed	N/R
	Entity 4	Title of Entity	N/R
		Functions Performed	N/R
	Entity 5	Title of Entity	N/R
		Functions Performed	N/R

Question	Option	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Question	Response
Provisions for revising decisions about health technologies and interventions once they are made.	N/R
Mechanism for translation or contextualization of evidence?	N/R

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Libya - HTA Country/Area Profile¹



Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Political support
	Rank 2	Awareness/Advocacy of the importance of HTA
	Rank 3	Institutionalization of HTA
	Rank 4	Qualified human resources
	Rank 5	Mandate from Policy Authority
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production capability	Rank 1	Budget availability
	Rank 2	Data Availability
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Malawi - HTA Country/Area Profile¹



Institutions & governance

Question	Response
Has a systematic process to support healthcare decision-making?	No
Please describe your health-care decision making process below.	There is no established standard body or committee for decision making. However, the process of revising the essential health package uses existing Technical Working Groups. The latest revision of the EHP involved the establishment of a special purpose TWG (EHP TWG) to act as the technical and advisory body. It is expected that the next revision will continue to use a multi-stakeholder platform such as the EHP TWG. The Process is to be participatory as possible with the technical team
Can you indicate whether there are plans for implementing a systematic formal process and if so, what that time-frame is?	There will be a process in place in 3-5 years
Any prioritization criteria used to determine which health technologies and interventions are considered in government health schemes in the country?	Yes
Is evidence collected for making decisions about the inclusion or exclusion of health technologies and interventions?	Yes
Are there any formal or informal procedures, rules, thresholds, or laws that factor in to the decision-making related to health technologies and interventions?	Yes

Question	Entity	Title/Function	Response
Entities(e.g. organizations/individuals/officials) involved in decisions regarding inclusion or exclusion of health technologies and interventions:	Entity 1	Title of Entity	Ministry of Health
		Functions Performed	identifying interventions, assessing evidence, appraising evidence, and making recommendations.
	Entity 2	Title of Entity	Development Organizations
		Functions Performed	assessing evidence and making decisions
	Entity 3	Title of Entity	International and Local NGOs
		Functions Performed	assessing evidence and making decisions
	Entity 4	Title of Entity	Academia
		Functions Performed	identifying interventions, assessing evidence, appraising evidence, and making recommendations.
	Entity 5	Title of Entity	Other Government Ministries and Agencies
		Functions Performed	assessing evidence and making decisions

Question	Option	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	Yes

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Malawi - HTA Country/Area Profile¹



Functions for which decision-making information is gathered?	Public Procurement of Medicines	No
	Protocols for public health programmes	Yes
	Other	N/R

Question	Response
Provisions for revising decisions about health technologies and interventions once they are made.	Yes
Mechanism for translation or contextualization of evidence?	Yes
Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA
	Rank 2	Institutionalization of HTA
	Rank 3	Political support
	Rank 4	Mandate from Policy Authority
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production capability	Rank 1	Budget availability
	Rank 2	Data Availability
	Rank 3	Knowledge of methods
	Rank 4	Dedicated human resources
	Rank 5	N/R

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Malaysia - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Technical Working Drug Committee, Technical Advisory Committee for Health Technology Assessment	Technical Advisory Committee for Health Technology Assessment	Technical Advisory Committee for Health Technology Assessment	Technical Advisory Committee for Health Technology Assessment	Technical Advisory Committee for Health Technology Assessment
Assessment	Formulary and Pharmacoeconomics Section, Pharmaceutical Services Division and MaHTAS	MaHTAS	MaHTAS	MaHTAS	MaHTAS
Recommendation	MOH Drug List Review Panel, Health Technology Assessment and Clinical Practice Guidelines Council	Health Technology Assessment and Clinical Practice Guidelines Council	Health Technology Assessment and Clinical Practice Guidelines Council	Health Technology Assessment and Clinical Practice Guidelines Council	Health Technology Assessment and Clinical Practice Guidelines Council

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Malaysia - HTA Country/Area Profile



Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	Yes	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	Yes
	National Health Service	Yes		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	21 to 50	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	Yes	If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	3-6 months
In the last 12 months, approximately how many assessments were performed?	60



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	Yes
If so, what is it?	The threshold is implicit. It was approved and used since 2015. 1 GDP per capita per QALY gain
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	No
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Malaysia - HTA Country/Area Profile



	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	No	No	Yes	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Dedicated human resources
	Rank 2	Qualified human resources		Rank 2	Data Availability
	Rank 3	Political support		Rank 3	Knowledge of methods
	Rank 4	Institutionalization of HTA		Rank 4	Budget availability
	Rank 5	Mandate from Policy Authority		Rank 5	Other Issues
	Rank 6	Other Issues			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Maldives - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	No
	Subnational Level	Yes
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	Some level of information is gathered for the functions mentioned above

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Maldives Food and Drug Authority	Quality Assurance and Regulation Division	Maldives Food and Drug Authority	Maldives Food and Drug Authority & Quality Assurance and Regulation Division	Health Protection Agency
Assessment	Maldives Food and Drug Authority	Quality Assurance and Regulation Division	Maldives Food and Drug Authority	Maldives Food and Drug Authority & Quality Assurance and Regulation Division	Health Protection Agency
Recommendation	Maldives Food and Drug Authority	Quality Assurance and Regulation Division	Maldives Food and Drug Authority	Maldives Food and Drug Authority & Quality Assurance and Regulation Division	Health Protection Agency

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Maldives - HTA Country/Area Profile



Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	No	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	Yes		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20	Are any resources received through private funding?	Yes
Allocated public sector budget?	No	If so, what percentage?	1



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	3



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	No
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Maldives - HTA Country/Area Profile



	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	Yes	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Other Issues	Barriers to Production Capability	Rank 1	Data Availability
	Rank 2	Qualified human resources		Rank 2	Budget availability
	Rank 3	Institutionalization of HTA		Rank 3	Dedicated human resources
	Rank 4	N/R		Rank 4	Other Issues
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Mali - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	Yes
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	DPM	DGSHP	DFM	DPM	DGSHP
Assessment	DFM	DGSHP	DFM	DPM	DGSHP
Recommendation	MSDS	MSDS	DGSHP/MSDS	MSDS	MSDS

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	Yes	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	Yes
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Mali - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R
Allocated public sector budget?	I don't know

Question	Response
Are any resources received through private funding?	N/R
If so, what percentage?	N/R



Assessments

Question	Response
How long does the assessment process take on average?	1-3 months
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	Yes
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	No



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	No
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	Yes	Yes	Yes	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Political support
	Rank 2	Qualified human resources
	Rank 3	Awareness/Advocacy of the importance of HTA
	Rank 4	Mandate from Policy Authority
	Rank 5	Institutionalization of HTA
	Rank 6	Other Issues

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Data Availability
	Rank 3	Dedicated human resources
	Rank 4	Knowledge of methods
	Rank 5	Other Issues

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Malta - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		N/A
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	No
	Other	Government Formulary Medicines Entitlement Protocols

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Committees within the Ministry for Health	N/R	N/R	N/R	N/R
Assessment	Directorate for Pharmaceutical Affairs	N/R	N/R	N/R	N/R
Recommendation	Ministry for Health	N/R	N/R	N/R	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
	Director of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	Yes	Do you assess impact?	N/R
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Malta - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20
Allocated public sector budget?	Yes

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	1-3 months
In the last 12 months, approximately how many assessments were performed?	34



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	N/R
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	Yes	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Political support
	Rank 2	Mandate from Policy Authority
	Rank 3	Awareness/Advocacy of the importance of HTA
	Rank 4	Qualified human resources
	Rank 5	Institutionalization of HTA
	Rank 6	Other Issues

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Data Availability
	Rank 3	Dedicated human resources
	Rank 4	Knowledge of methods
	Rank 5	Other Issues

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Mauritania - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Directorate of Pharmacy and Laboratories	Directorate of Pharmacy and Laboratories	Directorate of Pharmacy and Laboratories	Directorate of Pharmacy and Laboratories	Directorate General of Health
Assessment	Directorate of Pharmacy and Laboratories	General Directorate of Regulation, Organization of the Quality of Care and Services	Directorate of Pharmacy and Laboratories	Directorate of Pharmacy and Laboratories	Directorate General of Health
Recommendation	Directorate of Pharmacy and Laboratories, General Health Inspectorate, Central Purchasing of Essential Medicines and Consumables	Directorate of Pharmacy and Laboratories, General Health Inspectorate, Central Purchasing of Essential Medicines and Consumables	Directorate of Pharmacy and Laboratories, General Health Inspectorate, Central Purchasing of Essential Medicines and Consumables	Directorate of Pharmacy and Laboratories, General Health Inspectorate, Central Purchasing of Essential Medicines and Consumables	Directorate General of Health

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Mauritania - HTA Country/Area Profile



Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	1 to 5	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	Yes	If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	6-12 months
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	No



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	No
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Mauritania - HTA Country/Area Profile



	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	Yes



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Institutionalization of HTA	Barriers to Production Capability	Rank 1	Dedicated human resources
	Rank 2	Awareness/Advocacy of the importance of HTA		Rank 2	Knowledge of methods
	Rank 3	Political support		Rank 3	Data Availability
	Rank 4	Qualified human resources		Rank 4	Budget availability
	Rank 5	Other Issues		Rank 5	Other Issues
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Mauritius - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Pharmacy Board (PB)	Consultant-In-Charge (CIC)	Consultant-In-Charge (CIC)	Director Central Health Laboratory (CHL)	NITAG + Health Promotion Unit
Assessment	Pharmacy Board (PB)	Consultant-In-Charge (CIC)	Consultant-In-Charge (CIC)	Director Central Health Laboratory (CHL)	NITAG + NCDs and Health Promotion Unit
Recommendation	Pharmacy Board (PB) + Senior Chief Executive (SCE)	Consultant-In-Charge (CIC) + Senior Chief Executive (SCE)	Consultant-In-Charge (CIC) + Senior Chief Executive (SCE)	Senior Chief Executive (SCE) + Director Central Health Laboratory (CHL)	Senior Chief Executive (SCE) + NITAG + Health Promotion Unit

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	Yes
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	Yes		
	Other	N/R		

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Mauritius - HTA Country/Area Profile



Available Resources

Question	Response
How many professional staff (FTE) are involved in the HTA body?	Less than 1
Allocated public sector budget?	No

Question	Response
Are any resources received through private funding?	Yes
If so, what percentage?	1



Assessments

Question	Response
How long does the assessment process take on average?	3-6 months
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	Yes



Barriers

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Mauritius - HTA Country/Area Profile



Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Institutionalization of HTA	Barriers to Production Capability	Rank 1	Dedicated human resources
	Rank 2	Qualified human resources		Rank 2	Budget availability
	Rank 3	Awareness/Advocacy of the importance of HTA		Rank 3	Knowledge of methods
	Rank 4	Mandate from Policy Authority		Rank 4	Data Availability
	Rank 5	Political support		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Mexico - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	INTERINSTITUTIONAL COMMISSION OF THE BASIC TABLE AND CATALOG OF INPUTS OF THE HEALTH SECTOR / CENETEC	INTERINSTITUTIONAL COMMISSION OF THE BASIC TABLE AND CATALOG OF INPUTS OF THE HEALTH SECTOR / CENETEC	INTERINSTITUTIONAL COMMISSION OF THE BASIC TABLE AND CATALOG OF INPUTS OF THE HEALTH SECTOR / CENETEC	INTERINSTITUTIONAL COMMISSION OF THE BASIC TABLE AND CATALOG OF INPUTS OF THE HEALTH SECTOR / CENETEC	INTERINSTITUTIONAL COMMISSION OF THE BASIC TABLE AND CATALOG OF INPUTS OF THE HEALTH SECTOR / CENETEC
Assessment	INTERINSTITUTIONAL COMMISSION OF THE BASIC TABLE AND CATALOG OF INPUTS OF THE HEALTH SECTOR / CENETEC	INTERINSTITUTIONAL COMMISSION OF THE BASIC TABLE AND CATALOG OF INPUTS OF THE HEALTH SECTOR / CENETEC	INTERINSTITUTIONAL COMMISSION OF THE BASIC TABLE AND CATALOG OF INPUTS OF THE HEALTH SECTOR / CENETEC	INTERINSTITUTIONAL COMMISSION OF THE BASIC TABLE AND CATALOG OF INPUTS OF THE HEALTH SECTOR / CENETEC	INTERINSTITUTIONAL COMMISSION OF THE BASIC TABLE AND CATALOG OF INPUTS OF THE HEALTH SECTOR / CENETEC
Recommendation	INTERINSTITUTIONAL COMMISSION OF THE BASIC TABLE AND CATALOG OF INPUTS OF THE HEALTH SECTOR / CENETEC	INTERINSTITUTIONAL COMMISSION OF THE BASIC TABLE AND CATALOG OF INPUTS OF THE HEALTH SECTOR / CENETEC	INTERINSTITUTIONAL COMMISSION OF THE BASIC TABLE AND CATALOG OF INPUTS OF THE HEALTH SECTOR / CENETEC	INTERINSTITUTIONAL COMMISSION OF THE BASIC TABLE AND CATALOG OF INPUTS OF THE HEALTH SECTOR / CENETEC	INTERINSTITUTIONAL COMMISSION OF THE BASIC TABLE AND CATALOG OF INPUTS OF THE HEALTH SECTOR / CENETEC

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Mexico - HTA Country/Area Profile



Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	Yes	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R
	Department/Ministry of Health	Yes	Do you assess impact?	N/R
	National Health Service	Yes		
	Patient Organizations	No		
	Civil Society	No		
	Other	Yes		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R	Are any resources received through private funding?	N/R
Allocated public sector budget?	Yes	If so, what percentage?	N/R



Assessments

Question	Response
How long does the assessment process take on average?	1-3 months
In the last 12 months, approximately how many assessments were performed?	50



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Mexico - HTA Country/Area Profile



	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	Yes	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Institutionalization of HTA		Rank 2	Data Availability
	Rank 3	Mandate from Policy Authority		Rank 3	Knowledge of methods
	Rank 4	Political support		Rank 4	Dedicated human resources
	Rank 5	Qualified human resources		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Micronesia (Federated States of) - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	Yes
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	N/R	N/R	N/R	N/R	N/R
Assessment	N/R	N/R	N/R	N/R	N/R
Recommendation	N/R	N/R	N/R	N/R	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	No	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	No	If so, what percentage?	N/A

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Micronesia (Federated States of) - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	No



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Qualified human resources	Barriers to Production Capability	Rank 1	Dedicated human resources
	Rank 2	Awareness/Advocacy of the importance of HTA		Rank 2	Knowledge of methods
	Rank 3	Political support		Rank 3	Budget availability
	Rank 4	Institutionalization of HTA		Rank 4	Data Availability
	Rank 5	Mandate from Policy Authority		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Mongolia - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	N/R	N/R	N/R	N/R	N/R
Assessment	N/R	N/R	N/R	N/R	N/R
Recommendation	N/R	N/R	N/R	N/R	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	No	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	No	If so, what percentage?	N/A

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Mongolia - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	0



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	N/R
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/R
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Institutionalization of HTA	Barriers to Production Capability	Rank 1	Knowledge of methods
	Rank 2	Awareness/Advocacy of the importance of HTA		Rank 2	Budget availability
	Rank 3	Qualified human resources		Rank 3	Dedicated human resources
	Rank 4	Mandate from Policy Authority		Rank 4	Data Availability
	Rank 5	Political support		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Morocco - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		N/R

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Directorate of Medicines and Pharmacy	Department of Hospitals and Ambulatory Care	Directorate of Medicines and Pharmacy	Epidemiology and Disease Control Department	Directorate of Population
Assessment	Directorate of Medicines and Pharmacy	Department of Hospitals and Ambulatory Care	Directorate of Medicines and Pharmacy	Epidemiology and Disease Control Department	Directorate of Population
Recommendation	N/R	N/R	N/R	N/R	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	N/R
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Morocco - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	51 to 100
Allocated public sector budget?	Yes

Question	Response
Are any resources received through private funding?	Yes
If so, what percentage?	N/R



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	N/R
Do you have a database of health technology costs or prices?	N/R
Is there an officially endorsed cost-effectiveness threshold?	N/R
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	Yes	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Institutionalization of HTA
	Rank 2	Awareness/Advocacy of the importance of HTA
	Rank 3	Qualified human resources
	Rank 4	Mandate from Policy Authority
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Data Availability
	Rank 2	Dedicated human resources
	Rank 3	Budget availability
	Rank 4	Knowledge of methods
	Rank 5	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Mozambique - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	MoH and Partners	N/R	N/R	MoH and Partners	MoH and Partners
Assessment	MoH and Partners	N/R	N/R	MoH and Partners	MoH and Partners
Recommendation	MoH	N/R	N/R	MoH	MoH

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	Yes
	National Health Service	Yes		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	No	If so, what percentage?	N/A

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Mozambique - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	3-6 months
In the last 12 months, approximately how many assessments were performed?	3



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	No



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	Yes
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	Yes	No	No	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Dedicated human resources
	Rank 2	Institutionalization of HTA		Rank 2	Knowledge of methods
	Rank 3	Political support		Rank 3	Data Availability
	Rank 4	Mandate from Policy Authority		Rank 4	Budget availability
	Rank 5	Qualified human resources		Rank 5	Other Issues
	Rank 6	Other Issues			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Myanmar - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		N/R

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Procurement Section, Department of Public Health/Medical Care, Ministry of Health and Sports/ National Health Plan Implementation Monitoring Unit	N/R	N/R	N/R	N/R
Assessment	Procurement Section, Department of Public Health/Medical Care, Ministry of Health and Sports/ National Health Plan Implementation Monitoring Unit	N/R	N/R	N/R	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Myanmar - HTA Country/Area Profile



Recommendation	Procurement Section, Department of Public Health/Medical Care, Ministry of Health and Sports/ National Health Plan Implementation Monitoring Unit	N/R	N/R	N/R	N/R
----------------	---	-----	-----	-----	-----

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	1 to 5	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	No	If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	More than 1 year
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	No

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Question						Response
Is there a possibility to appeal against the decision?						N/R
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?						Yes
	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	Yes



Question	Ranking	Response
Barriers to Use	Rank 1	Mandate from Policy Authority
	Rank 2	Institutionalization of HTA
	Rank 3	Qualified human resources
	Rank 4	Political support
	Rank 5	Awareness/Advocacy of the importance of HTA
	Rank 6	Other Issues

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

 World Health Organization



Namibia - HTA Country/Area Profile¹



Institutions & governance

Question	Response
Has a systematic process to support healthcare decision-making?	No
Please describe your health-care decision making process below.	(there is some attempt being made but not systematic and adequate) To include new medicines in to our national essential medicines list, we use some criteria. the criteria is mainly related to clinical effectiveness and tcomprehensive economic analysis such as cost-effectiveness analysis is not done. We have used an external consultant to assist the Ministry in analysing cost effectiveness of essential medicines for our 7th edition NEMList that is under printing stage with financial support from WHO country office.
Can you indicate whether there are plans for implementing a systematic formal process and if so, what that time-frame is?	There will be a process in place in 1-2 years
Any prioritization criteria used to determine which health technologies and interventions are considered in government health schemes in the country?	Yes
Is evidence collected for making decisions about the inclusion or exclusion of health technologies and interventions?	Yes
Are there any formal or informal procedures, rules, thresholds, or laws that factor in to the decision-making related to health technologies and interventions?	Yes

Question	Entity	Title/Function	Response
Entities(e.g. organizations/individuals/officials) involved in decisions regarding inclusion or exclusion of health technologies and interventions:	Entity 1	Title of Entity	Health Care workers, Therapeutic Committees
		Functions Performed	Identify interventions for inclusion or exclusion
	Entity 2	Title of Entity	Essential Medicines List Committee (EMLC) secretariat
		Functions Performed	assess, appraise and recommned interventions
	Entity 3	Title of Entity	EMLC
		Functions Performed	Review recommendations and Make decisions
	Entity 4	Title of Entity	N/R
		Functions Performed	N/R
	Entity 5	Title of Entity	N/R
		Functions Performed	N/R

Question	Option	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Namibia - HTA Country/Area Profile¹



Functions for which decision-making information is gathered?	Objectives for pay-for-performance schemes	N/R
	Design of Health Benefit Packages	N/R
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	N/R
	Other	N/R

Question	Response
Provisions for revising decisions about health technologies and interventions once they are made.	Yes
Mechanism for translation or contextualization of evidence?	Yes
Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Political support
	Rank 2	Qualified human resources
	Rank 3	Awareness/Advocacy of the importance of HTA
	Rank 4	Institutionalization of HTA
	Rank 5	Mandate from Policy Authority
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production capability	Rank 1	Budget availability
	Rank 2	Dedicated human resources
	Rank 3	Data Availability
	Rank 4	Knowledge of methods
	Rank 5	N/R

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Nepal - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Department of Drug Administration	Professional Councils, National Health Training Centres	Quality Standard and Regulation Division, MoHP	National Public Health Laboratory	Policy, Planning and Management Division; Nepal Health Research Council
Assessment	Department of Drug Administration	Professional Councils, National Health Training Centres	Quality Standard and Regulation Division, MoHP	National Public Health Laboratory	Policy, Planning and Management Division; Nepal Health Research Council
Recommendation	Department of Drug Administration	Professional Councils, National Health Training Centres	Quality Standard and Regulation Division, MoHP	National Public Health Laboratory	Policy, Planning and Management Division; Nepal Health Research Council

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Nepal - HTA Country/Area Profile



Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	N/R	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	N/R	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	N/R	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	N/R		
	Patient Organizations	N/R		
	Civil Society	N/R		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	No	If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	1-3 months
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Nepal - HTA Country/Area Profile



	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	N/R	N/R	Yes	Yes	N/R	N/R



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Institutionalization of HTA		Rank 2	Dedicated human resources
	Rank 3	Qualified human resources		Rank 3	Knowledge of methods
	Rank 4	N/R		Rank 4	Data Availability
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Netherlands - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		N/A
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Yes	Yes	Yes	Yes	No
Assessment	No (manufacturer)	Yes	Yes	Yes	No
Recommendation	No (advice)	Yes	Yes	Yes	No

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	Yes
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	More than 100	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	Yes	If so, what percentage?	N/A

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Netherlands - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	3-6 months
In the last 12 months, approximately how many assessments were performed?	50



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	Yes
If so, what is it?	<p>Bol between 0.1 and 0.4 (proportional shortfall) ICER of max 20.000 euro/QALY Bol between 0.41 and 0.7 ICER of max 50.000 euro/QALY Bol between 0.71 and 1.0 ICER of max 80.999 euro/QALY</p> <p>Are reference values. Higher or lower values can be accepted because of contextual arguments (societal, rule of rescue, medical need, uncertainty of (cos) effectiveness a.s.o.</p>
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	Yes
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	Yes	Yes	Yes	No	No



Barriers

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Netherlands - HTA Country/Area Profile



Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Political support	Barriers to Production Capability	Rank 1	Data Availability
	Rank 2	Awareness/Advocacy of the importance of HTA		Rank 2	Budget availability
	Rank 3	Mandate from Policy Authority		Rank 3	Dedicated human resources
	Rank 4	Qualified human resources		Rank 4	Knowledge of methods
	Rank 5	Institutionalization of HTA		Rank 5	Other Issues
	Rank 6	Other Issues			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





New Zealand - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	PHARMAC	DHBs	DHBs	DHBs	Ministry of Health and PHARMAC (vaccines)
Assessment	PHARMAC and pharmaceutical suppliers	DHBs	DHBs	DHBs	Ministry of Health and PHARMAC (vaccine assessment)
Recommendation	PHARMAC	DHBs	DHBs and PHARMAC	DHBs	Ministry of Health and PHARMAC (vaccine funding)

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	No	Do you assess impact?	N/R
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	Yes		

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





New Zealand - HTA Country/Area Profile



Available Resources

Question	Response
How many professional staff (FTE) are involved in the HTA body?	More than 100
Allocated public sector budget?	Yes

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	More than 1 year
In the last 12 months, approximately how many assessments were performed?	40



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	Yes
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	Yes	Yes	Yes	No	No



Barriers

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



New Zealand - HTA Country/Area Profile



Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Qualified human resources	Barriers to Production Capability	Rank 1	Dedicated human resources
	Rank 2	Awareness/Advocacy of the importance of HTA		Rank 2	Data Availability
	Rank 3	Mandate from Policy Authority		Rank 3	Knowledge of methods
	Rank 4	Institutionalization of HTA		Rank 4	Budget availability
	Rank 5	Political support		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Nicaragua - HTA Country/Area Profile¹



Institutions & governance

Question	Response
Has a systematic process to support healthcare decision-making?	No
Please describe your health-care decision making process below.	National Health Policy, Human Development Plan and General Budget of the Republic
Can you indicate whether there are plans for implementing a systematic formal process and if so, what that time-frame is?	There will be a process in place in 3-5 years
Any prioritization criteria used to determine which health technologies and interventions are considered in government health schemes in the country?	N/R
Is evidence collected for making decisions about the inclusion or exclusion of health technologies and interventions?	No
Are there any formal or informal procedures, rules, thresholds, or laws that factor in to the decision-making related to health technologies and interventions?	N/R

Question	Entity	Title/Function	Response
Entities(e.g. organizations/individuals/officials) involved in decisions regarding inclusion or exclusion of health technologies and interventions:	Entity 1	Title of Entity	N/R
		Functions Performed	N/R
	Entity 2	Title of Entity	N/R
		Functions Performed	N/R
	Entity 3	Title of Entity	N/R
		Functions Performed	N/R
	Entity 4	Title of Entity	N/R
		Functions Performed	N/R
	Entity 5	Title of Entity	N/R
		Functions Performed	N/R

Question	Option	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Question	Response
Provisions for revising decisions about health technologies and interventions once they are made.	Yes
Mechanism for translation or contextualization of evidence?	No

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Nicaragua - HTA Country/Area Profile¹



Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA
	Rank 2	Institutionalization of HTA
	Rank 3	Qualified human resources
	Rank 4	N/R
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production capability	Rank 1	Data Availability
	Rank 2	Knowledge of methods
	Rank 3	Dedicated human resources
	Rank 4	N/R
	Rank 5	N/R

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Nigeria - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	Yes
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		N/A
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	FMOH	FMOH	N/R	NAFDAC	STATE MOH
Assessment	NIPRD,	NIMR	N/R	,NAFDAC, DFS,FMOH	HEALTHCARE FACILITIES
Recommendation	FMOH	FMOH	N/R	NAFDAC, FMOH	FMOH

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	Yes
	National Health Service	Yes		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Nigeria - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	1 to 5
Allocated public sector budget?	Yes

Question	Response
Are any resources received through private funding?	Yes
If so, what percentage?	18



Assessments

Question	Response
How long does the assessment process take on average?	1-3 months
In the last 12 months, approximately how many assessments were performed?	22



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	No



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	Yes



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Political support	Barriers to Production Capability	Rank 1	Knowledge of methods
	Rank 2	Awareness/Advocacy of the importance of HTA		Rank 2	Data Availability
	Rank 3	Institutionalization of HTA		Rank 3	Budget availability
	Rank 4	Qualified human resources		Rank 4	Dedicated human resources
	Rank 5	Mandate from Policy Authority		Rank 5	Other Issues
	Rank 6	Other Issues			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



North Macedonia - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Commission on Positive List	N/R	N/R	N/R	Ministry of Health
Assessment	Commission on Positive List	N/R	N/R	N/R	Ministry of Health
Recommendation	Health Insurance Fund	N/R	N/R	N/R	Ministry of Health

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	No	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





North Macedonia - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R
Allocated public sector budget?	Yes

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/R
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	Yes	No	No	No	Yes



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Mandate from Policy Authority
	Rank 2	Institutionalization of HTA
	Rank 3	Awareness/Advocacy of the importance of HTA
	Rank 4	Political support
	Rank 5	Qualified human resources
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Knowledge of methods
	Rank 2	Budget availability
	Rank 3	Dedicated human resources
	Rank 4	Data Availability
	Rank 5	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Norway - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	N/R
	Objectives for pay-for-performance schemes	N/R
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	N/R
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	N/R	N/R	N/R	N/R	N/R
Assessment	The Norwegian Medicine Agency	Norwegian Institute of Public Health	Norwegian Institute of Public Health	Norwegian Institute of Public Health	Norwegian Institute of Public Health and the Norwegian Directorate of Health
Recommendation	The Regional Health Authorities	The Regional Health Authorities	The Regional Health Authorities	The Regional Health Authorities	The Ministry of Health and Care services

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	N/R	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
	Director of the HTA or decision-making body	N/R	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R
	Department/Ministry of Health	N/R	Do you assess impact?	No
	National Health Service	N/R		
	Patient Organizations	N/R		
	Civil Society	N/R		
	Other	N/R		

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Norway - HTA Country/Area Profile



Available Resources

Question	Response
How many professional staff (FTE) are involved in the HTA body?	21 to 50
Allocated public sector budget?	Yes

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	6-12 months
In the last 12 months, approximately how many assessments were performed?	65



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	No
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	Yes	Yes	Yes	N/R	N/R



Barriers

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Norway - HTA Country/Area Profile



Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	N/R	Barriers to Production Capability	Rank 1	N/R
	Rank 2	N/R		Rank 2	N/R
	Rank 3	N/R		Rank 3	N/R
	Rank 4	N/R		Rank 4	N/R
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Occupied Palestinian territory, including east Jerusalem - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	MoH	MoH	MoH	MoH	MoH
Assessment	MoH	MoH	MoH	MoH	MoH
Recommendation	MoH	MoH	MoH	MoH	MoH

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	No	If so, what percentage?	N/A

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Occupied Palestinian territory, including east Jerusalem - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	3-6 months
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Knowledge of methods
	Rank 2	Political support		Rank 2	Dedicated human resources
	Rank 3	Institutionalization of HTA		Rank 3	Data Availability
	Rank 4	Mandate from Policy Authority		Rank 4	Budget availability
	Rank 5	Qualified human resources		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Oman - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		N/R

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Directorate General of Medical Supplied	DG of Quality	Directorate General of Engineering Affairs	Directorate General of Medical Supplied	DG of Quality
Assessment	Directorate General of Pharmaceutical Affairs & Drug Control	DG of Specialised Medical Services	Directorate General of Engineering Affairs	Directorate General of Medical Supplied	DG of Specialised Medical Services
Recommendation	Directorate General of Medical Supplied	DG of Specialised Medical Services	Directorate General of Engineering Affairs	Directorate General of Medical Supplied	Undersecretary level committee

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Oman - HTA Country/Area Profile



Available Resources

Question	Response
How many professional staff (FTE) are involved in the HTA body?	1 to 5
Allocated public sector budget?	No

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	6-12 months
In the last 12 months, approximately how many assessments were performed?	17



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	No



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	Yes
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	Yes



Barriers

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Oman - HTA Country/Area Profile



Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Institutionalization of HTA	Barriers to Production Capability	Rank 1	Dedicated human resources
	Rank 2	Qualified human resources		Rank 2	Knowledge of methods
	Rank 3	Awareness/Advocacy of the importance of HTA		Rank 3	Data Availability
	Rank 4	N/R		Rank 4	Budget availability
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Panama - HTA Country/Area Profile¹



Institutions & governance

Question	Response
Has a systematic process to support healthcare decision-making?	No
Please describe your health-care decision making process below.	N/R
Can you indicate whether there are plans for implementing a systematic formal process and if so, what that time-frame is?	There will be a process in place in 3-5 years
Any prioritization criteria used to determine which health technologies and interventions are considered in government health schemes in the country?	N/R
Is evidence collected for making decisions about the inclusion or exclusion of health technologies and interventions?	No
Are there any formal or informal procedures, rules, thresholds, or laws that factor in to the decision-making related to health technologies and interventions?	N/R

Question	Entity	Title/Function	Response
Entities(e.g. organizations/individuals/officials) involved in decisions regarding inclusion or exclusion of health technologies and interventions:	Entity 1	Title of Entity	N/R
		Functions Performed	N/R
	Entity 2	Title of Entity	N/R
		Functions Performed	N/R
	Entity 3	Title of Entity	N/R
		Functions Performed	N/R
	Entity 4	Title of Entity	N/R
		Functions Performed	N/R
	Entity 5	Title of Entity	N/R
		Functions Performed	N/R

Question	Option	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Question	Response
Provisions for revising decisions about health technologies and interventions once they are made.	N/R
Mechanism for translation or contextualization of evidence?	No

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Panama - HTA Country/Area Profile¹



Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA
	Rank 2	Institutionalization of HTA
	Rank 3	Mandate from Policy Authority
	Rank 4	Political support
	Rank 5	Qualified human resources
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production capability	Rank 1	Data Availability
	Rank 2	Knowledge of methods
	Rank 3	Dedicated human resources
	Rank 4	N/R
	Rank 5	N/R

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Papua New Guinea - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	National Department of Health	National Department of Health	National Department of Health	National Department of Health	National Department of Health
Assessment	National Department of Health	National Department of Health	National Department of Health	National Department of Health	National Department of Health
Recommendation	National Department of Health	National Department of Health	National Department of Health	National Department of Health	National Department of Health

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Papua New Guinea - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20
Allocated public sector budget?	Yes

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	1-3 months
In the last 12 months, approximately how many assessments were performed?	123



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	Yes	Yes	Yes	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Institutionalization of HTA	Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Mandate from Policy Authority		Rank 2	Dedicated human resources
	Rank 3	Qualified human resources		Rank 3	Knowledge of methods
	Rank 4	Awareness/Advocacy of the importance of HTA		Rank 4	Data Availability
	Rank 5	Political support		Rank 5	Other Issues
	Rank 6	Other Issues			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Paraguay - HTA Country/Area Profile¹



Institutions & governance

Question	Response
Has a systematic process to support healthcare decision-making?	No
Please describe your health-care decision making process below.	Demand vs Cost - profit. The Ministry of Health and Social Development entrusts independent bodies with the preparation of STD reports.
Can you indicate whether there are plans for implementing a systematic formal process and if so, what that time-frame is?	There is no plan to implement such a process
Any prioritization criteria used to determine which health technologies and interventions are considered in government health schemes in the country?	No
Is evidence collected for making decisions about the inclusion or exclusion of health technologies and interventions?	No
Are there any formal or informal procedures, rules, thresholds, or laws that factor in to the decision-making related to health technologies and interventions?	Yes

Question	Entity	Title/Function	Response
Entities(e.g. organizations/individuals/officials) involved in decisions regarding inclusion or exclusion of health technologies and interventions:	Entity 1	Title of Entity	N/R
		Functions Performed	N/R
	Entity 2	Title of Entity	N/R
		Functions Performed	N/R
	Entity 3	Title of Entity	N/R
		Functions Performed	N/R
	Entity 4	Title of Entity	N/R
		Functions Performed	N/R
	Entity 5	Title of Entity	N/R
		Functions Performed	N/R

Question	Option	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Question	Response
Provisions for revising decisions about health technologies and interventions once they are made.	N/R

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Paraguay - HTA Country/Area Profile¹



Mechanism for translation or contextualization of evidence?	No
Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA
	Rank 2	Institutionalization of HTA
	Rank 3	Political support
	Rank 4	Qualified human resources
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production capability	Rank 1	Budget availability
	Rank 2	Data Availability
	Rank 3	Knowledge of methods
	Rank 4	N/R
	Rank 5	N/R

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Peru - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Instituto Nacional de Salud / General Directorate of Medicines, Supplies and Drugs / Institute for Health Technology Assessment and Research	Instituto Nacional de Salud / General Directorate of Medicines, Supplies and Drugs / Institute for Health Technology Assessment and Research	Instituto Nacional de Salud / General Directorate of Medicines, Supplies and Drugs / Institute for Health Technology Assessment and Research	Instituto Nacional de Salud / General Directorate of Medicines, Supplies and Drugs / Institute for Health Technology Assessment and Research	National Institute of Health / General Directorate of Medicines, Supplies and Drugs / Institute for the Evaluation of Health Technologies and Research National Health Institute General Directorate of Medicines, Supplies and Drugs Institute for Health Technology Evaluation and Research
Assessment	Instituto Nacional de Salud / General Directorate of Medicines, Supplies and Drugs / Institute for Health Technology Assessment and Research	Instituto Nacional de Salud / General Directorate of Medicines, Supplies and Drugs / Institute for Health Technology Assessment and Research	Instituto Nacional de Salud / General Directorate of Medicines, Supplies and Drugs / Institute for Health Technology Assessment and Research	Instituto Nacional de Salud / General Directorate of Medicines, Supplies and Drugs / Institute for Health Technology Assessment and Research	National Health Institute / General Directorate of Medicines, Supplies and Drugs / Institute for the Evaluation of Health Technologies and Research

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Peru - HTA Country/Area Profile



Recommendation	Instituto Nacional de Salud / General Directorate of Medicines, Supplies and Drugs / Institute for Health Technology Assessment and Research	Instituto Nacional de Salud / General Directorate of Medicines, Supplies and Drugs / Institute for Health Technology Assessment and Research	Instituto Nacional de Salud / General Directorate of Medicines, Supplies and Drugs / Institute for Health Technology Assessment and Research	Instituto Nacional de Salud / General Directorate of Medicines, Supplies and Drugs / Institute for Health Technology Assessment and Research	National Health Institute / General Directorate of Medicines, Supplies and Drugs / Institute for the Evaluation of Health Technologies and Research
----------------	--	--	--	--	---

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R
	Department/Ministry of Health	No	Do you assess impact?	N/R
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R	Are any resources received through private funding?	N/R
Allocated public sector budget?	Yes	If so, what percentage?	N/R



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	43



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	N/R
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	N/R
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Peru - HTA Country/Area Profile



Recommendations

Question						Response
Is there a possibility to appeal against the decision?						N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?						No
	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Data Availability
	Rank 2	Institutionalization of HTA		Rank 2	Knowledge of methods
	Rank 3	Mandate from Policy Authority		Rank 3	Budget availability
	Rank 4	Qualified human resources		Rank 4	Dedicated human resources
	Rank 5	Political support		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Philippines - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	HTA Council	HTA Council	HTA Council	HTA Council	HTA Council
Assessment	HTA Unit and partner academics	HTA Unit and partner academics	HTA Unit and partner academics	HTA Unit and partner academics	HTA Unit and partner academics
Recommendation	HTA Council	HTA Council	HTA Council	HTA Council	HTA Council

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	Yes		
	Patient Organizations	Yes		
	Civil Society	Yes		
	Other	Yes		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Philippines - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	51 to 100
Allocated public sector budget?	Yes

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	More than 1 year
In the last 12 months, approximately how many assessments were performed?	12



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	No	Yes	Yes	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Qualified human resources
	Rank 2	Awareness/Advocacy of the importance of HTA
	Rank 3	Institutionalization of HTA
	Rank 4	Mandate from Policy Authority
	Rank 5	Political support
	Rank 6	Other Issues

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Dedicated human resources
	Rank 2	Data Availability
	Rank 3	Budget availability
	Rank 4	Knowledge of methods
	Rank 5	Other Issues

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Portugal - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	INFARMED, I.P.	INFARMED, I.P.	INFARMED, I.P.	INFARMED, I.P.	Directorate-General for Health
Assessment	INFARMED, I.P.	INFARMED, I.P.	INFARMED, I.P.	INFARMED, I.P.	Directorate-General for Health
Recommendation	Ministry of Health	Ministry of Health	Ministry of Health	Ministry of Health	Ministry of Health

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	Yes
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Portugal - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	21 to 50
Allocated public sector budget?	No

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	6-12 months
In the last 12 months, approximately how many assessments were performed?	102



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	Yes
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	No	No	No	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA
	Rank 2	Qualified human resources
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Other Issues
	Rank 2	Data Availability
	Rank 3	Knowledge of methods
	Rank 4	Dedicated human resources
	Rank 5	Budget availability

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Republic of Korea - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	N/R
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	N/R
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	N/R
	Protocols for public health programmes	N/R
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	N/R	Special committee	N/R	Special committee	Korea Centers for Disease Control and Prevention
Assessment	N/R	National Evidence-based healthcare Collaborating Agency(NECA)	N/R	National Evidence-based healthcare Collaborating Agency(NECA)	Korea Centers for Disease Control and Prevention
Recommendation	N/R	Committee on HTA (New Medical Technology Evaluation Committee)/ Medical Technology Reevaluation Committee	N/R	Committee on HTA (New Medical Technology Evaluation Committee)/ Medical Technology Reevaluation Committee	Korea Centers for Disease Control and Prevention

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Republic of Korea - HTA Country/Area Profile



Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	Yes	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R
	Department/Ministry of Health	N/R	Do you assess impact?	Yes
	National Health Service	N/R		
	Patient Organizations	N/R		
	Civil Society	N/R		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	More than 100	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	Yes	If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	6-12 months
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	N/R
Do you have a database of health technology costs or prices?	N/R
Is there an officially endorsed cost-effectiveness threshold?	N/R
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	Yes
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Republic of Korea - HTA Country/Area Profile



	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	N/R	N/R	Yes	N/R	N/R



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	N/R	Barriers to Production Capability	Rank 1	N/R
	Rank 2	N/R		Rank 2	N/R
	Rank 3	N/R		Rank 3	N/R
	Rank 4	N/R		Rank 4	N/R
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Republic of Moldova - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		N/A
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Council for compensated drugs	N/R	N/R	N/R	N/R
Assessment	National Health Insurance Company - secretariat of compensated drugs	N/R	N/R	N/R	N/R
Recommendation	Council for compensated drugs	N/R	N/R	N/R	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	No	Do you assess impact?	Yes
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Republic of Moldova - HTA Country/Area Profile



Available Resources

Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R
Allocated public sector budget?	Yes

Question	Response
Are any resources received through private funding?	N/R
If so, what percentage?	N/R



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	N/R
Is there an officially endorsed cost-effectiveness threshold?	Yes
If so, what is it?	there is no threshold
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Republic of Moldova - HTA Country/Area Profile



Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Institutionalization of HTA		Rank 2	Dedicated human resources
	Rank 3	Qualified human resources		Rank 3	Knowledge of methods
	Rank 4	Political support		Rank 4	Data Availability
	Rank 5	Mandate from Policy Authority		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Romania - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	MoH, NHIH	N/R	N/R	N/R	N/R
Assessment	NAMMDR	N/R	N/R	N/R	N/R
Recommendation	NAMMDR	N/R	N/R	N/R	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	Yes
	National Health Service	Yes		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	1 to 5	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	No	If so, what percentage?	N/A

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Romania - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	3-6 months
In the last 12 months, approximately how many assessments were performed?	120



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	N/R
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	Yes	No	No	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Knowledge of methods
	Rank 2	Qualified human resources		Rank 2	Dedicated human resources
	Rank 3	Mandate from Policy Authority		Rank 3	Data Availability
	Rank 4	Other Issues		Rank 4	Budget availability
	Rank 5	Institutionalization of HTA		Rank 5	Other Issues
	Rank 6	Political support			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Rwanda - HTA Country/Area Profile¹



Institutions & governance

Question	Response
Has a systematic process to support healthcare decision-making?	No
Please describe your health-care decision making process below.	There is a form process for compiling , analyzing and summarizing relevant information and scientific evidence to support health policy decision making
Can you indicate whether there are plans for implementing a systematic formal process and if so, what that time-frame is?	There will be a process in place in 1-2 years
Any prioritization criteria used to determine which health technologies and interventions are considered in government health schemes in the country?	Yes
Is evidence collected for making decisions about the inclusion or exclusion of health technologies and interventions?	Yes
Are there any formal or informal procedures, rules, thresholds, or laws that factor in to the decision-making related to health technologies and interventions?	Yes

Question	Entity	Title/Function	Response
Entities(e.g. organizations/individuals/officials) involved in decisions regarding inclusion or exclusion of health technologies and interventions:	Entity 1	Title of Entity	Ministry of Health
		Functions Performed	identifying interventions, assessing evidence, appraising evidence, and making recommendations.
	Entity 2	Title of Entity	Health insurance schemes
		Functions Performed	identifying interventions, assessing evidence, appraising evidence, and making recommendations.
	Entity 3	Title of Entity	patients associations
		Functions Performed	identifying interventions
	Entity 4	Title of Entity	Research institutions
		Functions Performed	identifying interventions and recommendations
	Entity 5	Title of Entity	Civil society
		Functions Performed	identifying interventions and recommendations.

Question	Option	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Rwanda - HTA Country/Area Profile¹



Question	Response
Provisions for revising decisions about health technologies and interventions once they are made.	Yes
Mechanism for translation or contextualization of evidence?	Yes
Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production capability	Rank 1	Knowledge of methods
	Rank 2	Mandate from Policy Authority		Rank 2	Data Availability
	Rank 3	Qualified human resources		Rank 3	Dedicated human resources
	Rank 4	Institutionalization of HTA		Rank 4	Budget availability
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



San Marino - HTA Country/Area Profile¹



Institutions & governance

Question	Response
Has a systematic process to support healthcare decision-making?	No
Please describe your health-care decision making process below.	Our country is a small state of only 35,00 people where universal coverage healthcare is provided. Health care choices are made on the basis of clinical needs and population response without technological assessment.
Can you indicate whether there are plans for implementing a systematic formal process and if so, what that time-frame is?	There will be a process in place in 1-2 years
Any prioritization criteria used to determine which health technologies and interventions are considered in government health schemes in the country?	No
Is evidence collected for making decisions about the inclusion or exclusion of health technologies and interventions?	No
Are there any formal or informal procedures, rules, thresholds, or laws that factor in to the decision-making related to health technologies and interventions?	No

Question	Entity	Title/Function	Response
Entities(e.g. organizations/individuals/officials) involved in decisions regarding inclusion or exclusion of health technologies and interventions:	Entity 1	Title of Entity	Executive Committee Istitute Health and Security
		Functions Performed	planning, management and acquisitions
	Entity 2	Title of Entity	Clinical Engeneering Istitute Health and Security
		Functions Performed	management and acquisitions technological instrumentation
	Entity 3	Title of Entity	Pharmaceutica Manager
		Functions Performed	management and acquisitions for medical device
	Entity 4	Title of Entity	N/R
		Functions Performed	N/R
	Entity 5	Title of Entity	N/R
		Functions Performed	N/R

Question	Option	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	Yes
	Other	N/R

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



San Marino - HTA Country/Area Profile¹



Question	Response
Provisions for revising decisions about health technologies and interventions once they are made.	No
Mechanism for translation or contextualization of evidence?	No
Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Other Issues
	Rank 2	Awareness/Advocacy of the importance of HTA
	Rank 3	Institutionalization of HTA
	Rank 4	Political support
	Rank 5	Mandate from Policy Authority
	Rank 6	Qualified human resources

Question	Ranking	Response
Barriers to Production capability	Rank 1	Other Issues
	Rank 2	Knowledge of methods
	Rank 3	Budget availability
	Rank 4	Data Availability
	Rank 5	Dedicated human resources

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Senegal - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		I don't know

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	DPM-PNA	DGES	PNA/CNAO	DL	DLM/DPRS
Assessment	PNA	DGES	DPM	DL	DSISS
Recommendation	CT CAPS	N/R	CT CAPS	CTBM	DPRS

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	Yes	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	Yes
	National Health Service	Yes		
	Patient Organizations	Yes		
	Civil Society	Yes		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20	Are any resources received through private funding?	N/R
Allocated public sector budget?	Yes	If so, what percentage?	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Senegal - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	3-6 months
In the last 12 months, approximately how many assessments were performed?	23



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	Yes	No	Yes	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Institutionalization of HTA	Barriers to Production Capability	Rank 1	Data Availability
	Rank 2	Awareness/Advocacy of the importance of HTA		Rank 2	Knowledge of methods
	Rank 3	Qualified human resources		Rank 3	Budget availability
	Rank 4	N/R		Rank 4	Dedicated human resources
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Serbia - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	Procedure of making a decision on the use of a new health technology

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	National Health Insurance Fund	Institute of Public Health of Serbia (IPHS)	Institute of Public Health of Serbia (IPHS)	Institute of Public Health of Serbia (IPHS)	National Health Insurance Fund
Assessment	National Health Insurance Fund	Institute of Public Health of Serbia (IPHS)	Institute of Public Health of Serbia (IPHS)	Institute of Public Health of Serbia (IPHS)	National Health Insurance Fund
Recommendation	National Health Insurance Fund	Ministry of Health	Ministry of Health	Ministry of Health	Ministry of Health

Question	Options	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No
	Executive Board of the HTA or decision-making body	No
	Director of the HTA or decision-making body	No
	Department/Ministry of Health	Yes
	National Health Service	Yes
	Patient Organizations	No
	Civil Society	No
	Other	N/R

Question	Response
Mechanism for translation or contextualization of evidence?	Yes
Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R
Do you assess impact?	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Serbia - HTA Country/Area Profile



Available Resources

Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20
Allocated public sector budget?	No

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/R
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	Yes



Barriers

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Serbia - HTA Country/Area Profile



Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Qualified human resources	Barriers to Production Capability	Rank 1	Dedicated human resources
	Rank 2	Awareness/Advocacy of the importance of HTA		Rank 2	Knowledge of methods
	Rank 3	Mandate from Policy Authority		Rank 3	Data Availability
	Rank 4	Institutionalization of HTA		Rank 4	Budget availability
	Rank 5	Other Issues		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Seychelles - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	N/R	N/R	N/R	N/R	N/R
Assessment	Yes	Yes	Yes	Yes	Yes
Recommendation	Yes	Yes	Yes	Yes	Yes

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R
	Department/Ministry of Health	Yes	Do you assess impact?	Yes
	National Health Service	No		
	Patient Organizations	Yes		
	Civil Society	Yes		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	Less than 1	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	Yes	If so, what percentage?	N/A

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Seychelles - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	More than 1 year
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	No



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	Yes	Yes	Yes	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Political support
	Rank 2	Institutionalization of HTA
	Rank 3	Awareness/Advocacy of the importance of HTA
	Rank 4	Qualified human resources
	Rank 5	Mandate from Policy Authority
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Data Availability
	Rank 3	Dedicated human resources
	Rank 4	Knowledge of methods
	Rank 5	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Sierra Leone - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	Yes
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	Service delivery

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Chief Medical Officer	CMO	CMO	CMO	CMO
Assessment	Pharmacy Board	Medical and Dental Council Sierra Leone	Directorate of Pharmaceutical Services	Directorate of Laboratory and Safe Blood Services	National and District levels
Recommendation	CMO	CMO	CMO	CMO	CMO

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	Yes		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Sierra Leone - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R
Allocated public sector budget?	N/R

Question	Response
Are any resources received through private funding?	N/R
If so, what percentage?	N/R



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	N/R
Do you have a database of health technology costs or prices?	N/R
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	No



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	Yes	Yes	Yes	No	Yes



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Dedicated human resources
	Rank 2	Political support		Rank 2	Knowledge of methods
	Rank 3	Mandate from Policy Authority		Rank 3	Budget availability
	Rank 4	Qualified human resources		Rank 4	Other Issues
	Rank 5	Other Issues		Rank 5	Data Availability
	Rank 6	Institutionalization of HTA			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Singapore - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	MOH Drug Advisory Committee	MOH Medical Technology Advisory Committee	MOH Medical Technology Advisory Committee	MOH Medical Technology Advisory Committee	Vaccines = MOH Drug Advisory Committee
Assessment	Agency for Care Effectiveness (ACE), MOH Singapore; Independent Evidence Review Centres	Agency for Care Effectiveness (ACE), MOH Singapore	Agency for Care Effectiveness (ACE), MOH Singapore	Agency for Care Effectiveness (ACE), MOH Singapore	Vaccines = Agency for Care Effectiveness (ACE), Ministry of Health Singapore
Recommendation	MOH Drug Advisory Committee	MOH Medical Technology Advisory Committee	MOH Medical Technology Advisory Committee	MOH Medical Technology Advisory Committee	Vaccines = MOH Drug Advisory Committee and Expert Committee on Immunisation

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Singapore - HTA Country/Area Profile



Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	Yes
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	Yes		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	51 to 100	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	Yes	If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	3-6 months
In the last 12 months, approximately how many assessments were performed?	108



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Singapore - HTA Country/Area Profile



	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	Yes	Yes	Yes	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Data Availability
	Rank 2	Qualified human resources		Rank 2	Dedicated human resources
	Rank 3	N/R		Rank 3	N/R
	Rank 4	N/R		Rank 4	N/R
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Slovakia - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Ministry of Health	Health Insurance Funds	Ministry of Health	Health Insurance Funds	Ministry of Health
Assessment	Ministry of Health	Health Insurance Funds	Ministry of Health	Health Insurance Funds	Ministry of Health
Recommendation	Ministry of Health	Health Insurance Funds	Ministry of Health	Health Insurance Funds	Ministry of Health

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	N/R	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	N/R	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	N/R	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	N/R		
	Patient Organizations	N/R		
	Civil Society	N/R		
	Other	Yes		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Slovakia - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20
Allocated public sector budget?	Yes

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	3-6 months
In the last 12 months, approximately how many assessments were performed?	54



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	Yes
If so, what is it?	Lower (λ_1) and upper (λ_2) cost-effectiveness thresholds were defined as 35 and 41 times the average monthly salary. Tesar T, Obsitnik B, Kaló Z and Kristensen FB (2019) How Changes in Reimbursement Practices Influence the Financial Sustainability of Medicine Policy: Lessons Learned from Slovakia. Front. Pharmacol. 10:664.doi: 10.3389/fphar.2019.00664
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	Yes
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	Yes	Yes	Yes	Yes	N/R



Barriers

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Slovakia - HTA Country/Area Profile



Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Dedicated human resources
	Rank 2	Political support		Rank 2	Knowledge of methods
	Rank 3	Qualified human resources		Rank 3	Budget availability
	Rank 4	Institutionalization of HTA		Rank 4	Data Availability
	Rank 5	Mandate from Policy Authority		Rank 5	Other Issues
	Rank 6	Other Issues			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Slovenia - HTA Country/Area Profile¹



Institutions & governance

Question	Response
Has a systematic process to support healthcare decision-making?	No
Please describe your health-care decision making process below.	There is no dedicated health technology assessment (HTA) agency or national regulatory HTA framework for introducing new health technologies into the system of public financing in Slovenia, yet. However, elements of HTA are included in the pricing and reimbursement procedures for pharmaceuticals, and also for some other health technologies. HTA is very segmented and on different level according to type of technology.
Can you indicate whether there are plans for implementing a systematic formal process and if so, what that time-frame is?	N/R
Any prioritization criteria used to determine which health technologies and interventions are considered in government health schemes in the country?	Yes
Is evidence collected for making decisions about the inclusion or exclusion of health technologies and interventions?	No
Are there any formal or informal procedures, rules, thresholds, or laws that factor in to the decision-making related to health technologies and interventions?	Yes

Question	Entity	Title/Function	Response
Entities(e.g. organizations/individuals/officials) involved in decisions regarding inclusion or exclusion of health technologies and interventions:	Entity 1	Title of Entity	Health Insurance Institute
		Functions Performed	N/R
	Entity 2	Title of Entity	Ministry of Health
		Functions Performed	N/R
	Entity 3	Title of Entity	Hospitals and other health care providers
		Functions Performed	N/R
	Entity 4	Title of Entity	N/R
		Functions Performed	N/R
	Entity 5	Title of Entity	N/R
		Functions Performed	N/R

Question	Option	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	No

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Slovenia - HTA Country/Area Profile¹



Functions for which decision-making information is	Other	N/R
Question		Response
Provisions for revising decisions about health technologies and interventions once they are made.		No
Mechanism for translation or contextualization of evidence?		No
Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?		No
Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?		No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Institutionalization of HTA	Barriers to Production capability	Rank 1	Dedicated human resources
	Rank 2	Mandate from Policy Authority		Rank 2	Budget availability
	Rank 3	Qualified human resources		Rank 3	Knowledge of methods
	Rank 4	N/R		Rank 4	N/R
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Solomon Islands - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	National Medical Store	N/R	N/R	N/R	N/R
Assessment	Pharmacies	N/R	N/R	Laboratories	N/R
Recommendation	N/R	N/R	N/R	N/R	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Solomon Islands - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	1 to 5
Allocated public sector budget?	Yes

Question	Response
Are any resources received through private funding?	Yes
If so, what percentage?	40



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	Yes
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	Yes	Yes	Yes	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA
	Rank 2	Institutionalization of HTA
	Rank 3	Mandate from Policy Authority
	Rank 4	Qualified human resources
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Dedicated human resources
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Somalia - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	Yes
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	Essential Package of Health Services

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	MOH, WHO, UNICEF	MOH, WHO, UNICEF	MOH, WHO	MOH, WHO	MOH, WHO, UNICEF
Assessment	UNICEF, WHO	WHO	WHO	WHO	UNICEF
Recommendation	MoH	MoH	MoH	MoH	MoH

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	Yes		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Somalia - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	1 to 5
Allocated public sector budget?	No

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	6-12 months
In the last 12 months, approximately how many assessments were performed?	1



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	No



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	Yes	Yes



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Political support
	Rank 2	Mandate from Policy Authority
	Rank 3	Awareness/Advocacy of the importance of HTA
	Rank 4	Institutionalization of HTA
	Rank 5	Qualified human resources
	Rank 6	Other Issues

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Data Availability
	Rank 2	Knowledge of methods
	Rank 3	Dedicated human resources
	Rank 4	Budget availability
	Rank 5	Other Issues

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



South Africa - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	NDoH	N/R	NDoH	NDoH, PHC ELL	N/R
Assessment	NDoH	N/R	NDoH	NDoH, PHC ELL	N/R
Recommendation	NDoH	N/R	NDoH	NDoH, PHC ELL	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	Yes		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	1 to 5	Are any resources received through private funding?	Yes
Allocated public sector budget?	No	If so, what percentage?	10

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





South Africa - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	6-12 months
In the last 12 months, approximately how many assessments were performed?	40



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	Yes
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	No	Yes	Yes	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Institutionalization of HTA
	Rank 2	Qualified human resources
	Rank 3	Awareness/Advocacy of the importance of HTA
	Rank 4	Political support
	Rank 5	Mandate from Policy Authority
	Rank 6	Other Issues

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Dedicated human resources
	Rank 2	Budget availability
	Rank 3	Knowledge of methods
	Rank 4	Data Availability
	Rank 5	Other Issues

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



South Sudan - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Ministry of Health and Health sector partners	N/R	N/R	N/R	Ministry of Health and all health sector partners
Assessment	Ministry of Health, WHO, key partners (WHO, UNICEF, UNFPA, UNAIDS)	N/R	N/R	N/R	Ministry of Health; partners (WHO, UNICEF, UNFPA, UNAIDS)
Recommendation	Ministry of Health	N/R	N/R	N/R	Ministry of Health

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





South Sudan - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	Less than 1
Allocated public sector budget?	No

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA
	Rank 2	Institutionalization of HTA
	Rank 3	Qualified human resources
	Rank 4	Mandate from Policy Authority
	Rank 5	Political support
	Rank 6	Other Issues

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Knowledge of methods
	Rank 2	Dedicated human resources
	Rank 3	Data Availability
	Rank 4	Budget availability
	Rank 5	Other Issues

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Spain - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	Yes
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	REvalMed/Subdirectorato General for Pharmacy	RedETS	RedETS	RedETS	RedETS
Assessment	REvalMed	Spanish Network of Health Technology Assessment Agencies and SNS Benefits (RedETS)	RedETS	RedETS	RedETS
Recommendation	CIPM (Interministerial Commission on Drug Prices)	Benefits, Insurance and Financing Commission (CPAF)	CPAF	CPAF	Public Health Commission

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Spain - HTA Country/Area Profile



Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	Yes		
	Patient Organizations	Yes		
	Civil Society	No		
	Other	Yes		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	51 to 100	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	Yes	If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	6-12 months
In the last 12 months, approximately how many assessments were performed?	85



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	Yes

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Spain - HTA Country/Area Profile



Question	Response
If so, what is it?	In the report on the Monetary Value of a Quality-Adjusted Life Year: Empirical estimation of the opportunity cost in the National Health System empirical estimation of the opportunity cost in terms of QALY that can be used as a tool for setting the cost threshold -Effectiveness in Spain in the context of previously assigned budgets. This estimate is based on the best available evidence, but cannot be considered an exact figure. Therefore, it is recommended to use a range between € 20,000 and € 25,000 as a cost-effectiveness threshold in these contexts. Updating this figure periodically using more recent information is also considered necessary for its optimal use as a reference for the cost-effectiveness threshold.
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question						Response
Is there a possibility to appeal against the decision?						N/R
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?						Yes
	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	No	No	Yes	Yes	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Data Availability
	Rank 2	Institutionalization of HTA		Rank 2	Dedicated human resources
	Rank 3	Qualified human resources		Rank 3	Budget availability
	Rank 4	Mandate from Policy Authority		Rank 4	Knowledge of methods
	Rank 5	Political support		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Sri Lanka - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	N/R
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	N/R
	Indicators of quality of care	N/R
	Objectives for pay-for-performance schemes	N/R
	Design of Health Benefit Packages	N/R
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	N/R
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	MSD	N/R	MSD/BME	MSD	FHB/EPIC
Assessment	NMRA/MSD	N/R	MSD/BME	MSD	FHB/EPIC
Recommendation	MSD	N/R	MSD/BME	MSD	FHB/EPIC

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	N/R	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	N/R	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	N/R	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	N/R		
	Patient Organizations	N/R		
	Civil Society	N/R		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	Yes	If so, what percentage?	N/A

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Sri Lanka - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	N/R	Yes	Yes	Yes	Yes	N/R



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Mandate from Policy Authority	Barriers to Production Capability	Rank 1	Dedicated human resources
	Rank 2	Political support		Rank 2	Knowledge of methods
	Rank 3	Institutionalization of HTA		Rank 3	Data Availability
	Rank 4	Awareness/Advocacy of the importance of HTA		Rank 4	Budget availability
	Rank 5	Qualified human resources		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Sweden - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	Yes
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	N/R
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	N/R
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	N/R
	Other	Could be for any decision regarding provision of health care interventions (prevention, diagnostics, pharma, medical devices, surgical procedures, psychological treatment etc). Indicators - public health determinants and health outcome.

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	TLV, The National Board of Health and Welfare (NBHW), the New Therapies Council (SALAR) or the 21 Regions	NBHW or the 21 Regions	NBHW, TLV, Medical Technology Council (SALAR) or the 21 Regions	NBHW, Medical Technology Council (SALAR) and the 21 regions, (TLV)	NBHW, PHAS or the 21 Regions
Assessment	TLV, SBU	SBU	SBU, TLV	SBU, (TLV)	SBU, Public Health Agency Sweden (PHAS)
Recommendation	TLV, NBHW and the New Therapies Council (represents the 21 regions) for inpatient care at hospitals	NBHW or the 21 Regions	NBHW, TLV and Medical Technology Council (SALAR), the 21 Regions	NBHW and the 21 regions, (TLV)	NBHW, PHAS or the MoH for eg. vaccination programs and the 21 Regions

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Sweden - HTA Country/Area Profile



Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	Yes	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	Yes	Do you assess impact?	Yes
	National Health Service	Yes		
	Patient Organizations	Yes		
	Civil Society	N/R		
	Other	Yes		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	More than 100	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	Yes	If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	More than 1 year
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Sweden - HTA Country/Area Profile



	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	Yes	Yes	Yes	N/R	N/R



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Other Issues	Barriers to Production Capability	Rank 1	Other Issues
	Rank 2	Awareness/Advocacy of the importance of HTA		Rank 2	Budget availability
	Rank 3	Political support		Rank 3	N/R
	Rank 4	Qualified human resources		Rank 4	N/R
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Switzerland - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		N/A
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	N/R
	Planning and budgeting	N/R
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	N/R
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	N/R
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Federal pharmaceutical commission	Federal commission for general services and principles	Federal commission for analyses, aids and equipment	Federal commission for analyses, aids and equipment	Federal commission for general services and principles
Assessment	Section HTA	Section HTA	Section HTA	Section HTA	Section HTA
Recommendation	Federal Office of Public Health	Federal Department of Home Affairs	Federal Department of Home Affairs	Federal Department of Home Affairs	Federal Department of Home Affairs

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	Yes	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	N/R	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
	Director of the HTA or decision-making body	N/R	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	N/R		
	Patient Organizations	N/R		
	Civil Society	N/R		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Switzerland - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20
Allocated public sector budget?	Yes

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	6-12 months
In the last 12 months, approximately how many assessments were performed?	13



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/R
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	N/R	N/R	N/R	N/R	N/R



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Data Availability
	Rank 2	Institutionalization of HTA		Rank 2	Budget availability
	Rank 3	Mandate from Policy Authority		Rank 3	Dedicated human resources
	Rank 4	Qualified human resources		Rank 4	Other Issues
	Rank 5	Other Issues		Rank 5	Knowledge of methods
	Rank 6	Political support			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Syrian Arab Republic - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	Yes
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	N/R	Directorate of Primary Health Care - Directorate of Hospitals - Directorate of Mental Health - Directorate of Communicable and Chronic Diseases - and Director of Ambulance and Emergency	Directorate of Medical Engineering and Maintenance	N/R	Directorate of Primary Health Care - Directorate of Hospitals - Directorate of Mental Health - Directorate of Communicable and Chronic Diseases - and Director of Ambulance and Emergency
Assessment	Directorate of Communicable and Chronic Diseases	Directorate of health care - hospitals - mental health - ambulance and emergency - communicable and chronic diseases	Directorate of Medical Engineering and Maintenance / Directorate of Medical Equipment and Supplies	N/R	Directorate of Primary Health Care - Directorate of Hospitals - Directorate of Mental Health - Directorate of Communicable and Chronic Diseases - and Director of Ambulance and Emergency

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Syrian Arab Republic - HTA Country/Area Profile



Recommendation	N/R	Directorate of Primary Health Care - Directorate of Hospitals - Directorate of Mental Health - Directorate of Communicable and Chronic Diseases - Director of Ambulance and Emergency	Directorate of Planning and International Cooperation + Directorate of Medical Engineering and Maintenance / Directorate of Contracts	N/R	Directorate of Primary Health Care - Directorate of Hospitals - Directorate of Mental Health - Directorate of Communicable and Chronic Diseases - Director of Ambulance and Emergency
----------------	-----	---	---	-----	---

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	Yes
	National Health Service	Yes		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	More than 100	Are any resources received through private funding?	N/R
Allocated public sector budget?	N/R	If so, what percentage?	N/R



Assessments

Question	Response
How long does the assessment process take on average?	1-3 months
In the last 12 months, approximately how many assessments were performed?	12



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	N/R
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	N/R
If so, what is it?	N/A

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Syrian Arab Republic - HTA Country/Area Profile



Question	Response
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	Yes
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Qualified human resources	Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Institutionalization of HTA		Rank 2	Dedicated human resources
	Rank 3	Awareness/Advocacy of the importance of HTA		Rank 3	Knowledge of methods
	Rank 4	Other Issues		Rank 4	Data Availability
	Rank 5	N/R		Rank 5	Other Issues
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Tajikistan - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		I don't know

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	State Unitary Enterprise "Expertise and testing of pharmaceutical and medical products"	State Institution "Center for Medical Accreditation"	State Unitary Enterprise "Expertise and testing of pharmaceutical and medical products"	State Unitary Enterprise "Expertise and testing of pharmaceutical and medical products"	N/R
Assessment	State Unitary Enterprise "Expertise and Testing of Pharmaceutical and Medical Products - State Supervision Service for Healthcare and Social Protection of the Population"	State Institution "Center for Medical Accreditation"	State Unitary Enterprise "Expertise and testing of pharmaceutical and medical products"	State Unitary Enterprise "Expertise and testing of pharmaceutical and medical products"	At the level of responsible institutions
Recommendation	State Unitary Enterprise "Expertise and testing of pharmaceutical and medical products"	Accreditation Council under the Ministry of Health	State Unitary Enterprise "Expertise and testing of pharmaceutical and medical products"	State Unitary Enterprise "Expertise and testing of pharmaceutical and medical products"	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Tajikistan - HTA Country/Area Profile



Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	N/R	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	N/R	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
	Director of the HTA or decision-making body	N/R	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	N/R	Do you assess impact?	Yes
	National Health Service	Yes		
	Patient Organizations	N/R		
	Civil Society	N/R		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20	Are any resources received through private funding?	Yes
Allocated public sector budget?	Yes	If so, what percentage?	10



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	26



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	Yes
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Tajikistan - HTA Country/Area Profile



	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	N/R	N/R	N/R	N/R	N/R	N/R



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Other Issues	Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Awareness/Advocacy of the importance of HTA		Rank 2	Dedicated human resources
	Rank 3	Qualified human resources		Rank 3	N/R
	Rank 4	N/R		Rank 4	N/R
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Thailand - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Food and Drug Administration, Health System Research Institute (HSRI)	National Health Security Office (NHSO), Health System Research Institute (HSRI)	National Health Security Office (NHSO), Health System Research Institute (HSRI)	National Health Security Office (NHSO), Health System Research Institute (HSRI)	National Health Security Office (NHSO), Health System Research Institute (HSRI)
Assessment	Academic Institutes (e.g., universities, research institutes)	Academic Institutes (e.g., universities, research institutes)	Academic Institutes (e.g., universities, research institutes)	Academic Institutes (e.g., universities, research institutes)	Academic Institutes (e.g., universities, research institutes)
Recommendation	Sub-Committee for the Development of the National List of Essential Medicines	National Health Security Office (NHSO) Board	National Health Security Office (NHSO) Board	National Health Security Office (NHSO) Board	National Health Security Office (NHSO) Board

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Thailand - HTA Country/Area Profile



Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	Yes	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	Yes		
	Patient Organizations	Yes		
	Civil Society	Yes		
	Other	Yes		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	51 to 100	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	No	If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	More than 1 year
In the last 12 months, approximately how many assessments were performed?	30



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	Yes
If so, what is it?	The cost-effectiveness threshold in Thailand is THB 160,000/QALY gained. It has been in use since 2013.
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/R
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Thailand - HTA Country/Area Profile



	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	No	Yes	Yes	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Qualified human resources	Barriers to Production Capability	Rank 1	Dedicated human resources
	Rank 2	Awareness/Advocacy of the importance of HTA		Rank 2	Budget availability
	Rank 3	Institutionalization of HTA		Rank 3	Data Availability
	Rank 4	Political support		Rank 4	Knowledge of methods
	Rank 5	Mandate from Policy Authority		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Institutions & governance

Question	Response
Has a systematic process to support healthcare decision-making?	No
Please describe your health-care decision making process below.	<p>There are no HTA bodies in Timor-Leste or HTA is not institutionalized. The health care services in Timor-Leste is universally free and financed mainly from the government budget complemented with donor support. The health system configuration in Timor-Leste consists of the Central Services, which responsible for governance/leadership and financing health service delivery at the municipal level; while there are autonomous agencies such as the Central Pharmacy, the National Health Laboratory, the National Institute of Health and The National Hospitals. While these autonomous agencies are administratively independent; health care decision making is made at the Council of Director Level, which is presided by the Minister of Health. However; given there is no system in place for strategic purchases; decisions are often made at various institutions without proper coordination. For example, the National Hospital decides on new technologies to be introduced based on needs and funding availability. The National Health Laboratory will decide on the types of diagnostic services to be provided at each health care facility. For Primacar care level, services are offered based on the Essential Services Package established by the Ministry of Health; and procurement of medicines is based on the Essential Medicine List. In addition, there are existing technical working groups that serve as advisory bodies to the Ministry of Health, such as the Immunization Technical Working group who advises the Ministry of Health on what type of vaccine to introduce; based on its clinical effectiveness, safety, cost-effectiveness. Hence in general, there is no systematic decision making in place and rather fragmented within the ministry of health directorates and its autonomous institution. Factors such as clinical effectiveness, safety, impact on health outcome, cost-effectiveness, budget impact, social and ethical aspect are considered to some extent; however without in-depth analysis or evidence-based assessment. Adhoc Technical Working Group which include stakeholder participation often forms if any decision to be made before a new intervention is introduced.</p>
Can you indicate whether there are plans for implementing a systematic formal process and if so, what that time-frame is?	There will be a process in place in 3-5 years
Any prioritization criteria used to determine which health technologies and interventions are considered in government health schemes in the country?	No
Is evidence collected for making decisions about the inclusion or exclusion of health technologies and interventions?	Yes

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Timor-Leste - HTA Country/Area Profile¹



Are there any formal or informal procedures, rules, thresholds, or laws that factor in to the decision-making related to health technologies and interventions?	Yes
---	-----

Question	Entity	Title/Function	Response
Entities(e.g. organizations/individuals/officials) involved in decisions regarding inclusion or exclusion of health technologies and interventions:	Entity 1	Title of Entity	Council of Director - MoH
		Functions Performed	Review and Approval of of Policy or intervention
	Entity 2	Title of Entity	Medical Board
		Functions Performed	Review patient's clinical status and approve for overseas referral
	Entity 3	Title of Entity	National Immunization Technical Advisory Group
		Functions Performed	Evidence review and recommend vaccine introduction
	Entity 4	Title of Entity	National Directorate of Pharmacy and Medicine
		Functions Performed	Review and approve essential medicine list
	Entity 5	Title of Entity	National Hospital & National Laboratory
		Functions Performed	two autonomous institution that has competency to decide new technology to be procured for clinical and diagnostic

Question	Option	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Question	Response
Provisions for revising decisions about health technologies and interventions once they are made.	N/R
Mechanism for translation or contextualization of evidence?	No
Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Qualified human resources
	Rank 2	Awareness/Advocacy of the importance of HTA

Question	Ranking	Response
Barriers to Production capability	Rank 1	Dedicated human resources
	Rank 2	Data Availability
	Rank 3	Knowledge of methods

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Timor-Leste - HTA Country/Area Profile¹



Barriers to Use	Rank 3	Other Issues
	Rank 4	Mandate from Policy Authority
	Rank 5	Institutionalization of HTA
	Rank 6	Political support

Barriers to Production	Rank 4	Budget availability
	Rank 5	Other Issues

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Trinidad and Tobago - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		N/R
Existence of standard methodology or process guideline?		N/A
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		N/R

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	N/R	N/R	N/R	N/R	N/R
Assessment	N/R	N/R	N/R	N/R	N/R
Recommendation	N/R	N/R	N/R	N/R	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	N/R
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	N/R
	Department/Ministry of Health	No	Do you assess impact?	N/R
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R	Are any resources received through private funding?	N/R
Allocated public sector budget?	N/R	If so, what percentage?	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Trinidad and Tobago - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	N/R



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	N/R
Do you have a database of health technology costs or prices?	N/R
Is there an officially endorsed cost-effectiveness threshold?	N/R
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	N/R



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	N/R
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	N/R
	Rank 2	N/R
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R
	Rank 6	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Tunisia - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	coverage of technologies/interventions are the main decisions informed by HTA in Tunisia. Informing price negotiations in the framework of reimbursement

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	See above	See above	See above	See above	See above
Assessment	Coverage decisions are taken by the benefit package committee (commission de révision du régime de base) under the auspices of ministry of social affairs. NB : Going through the INEAS HTA process to take a coverage decision is not mandatory yet in Tunisia. INEAS is commissioned on a case-by-case basis. An agreement setting out the terms of collaboration between CNAM	Same procedure than for pharmaceuticals	Same procedure than for pharmaceuticals	Same procedure. NB some decisions on DT are taken by the benefit package committee but some other decisions on acquisition of DT are taken by ministry of health. In both cases, the process of INEAS follows the same principle than for pharmaceuticals	Decisions on this type of intervention are taken by ministry of health. NB : Going through the INEAS HTA process to take a coverage decision is not mandatory yet in Tunisia. INEAS is commissioned on a case-by-case basis. When INEAS is commissioned to evaluate this type of interventions, the assessment is performed at INEAS, a multidisciplinary technical advisory

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Tunisia - HTA Country/Area Profile



	and INEAS is currently being discussed/finalised . When INEAS is commissioned to evaluate a medicine for reimbursement purposes (in general high priced medicines), the assessment is performed at INEAS, a multidisciplinary technical advisory group (TAG) including representatives of CNAM (compulsory insurance scheme) is appointed and consulted by INEAS during the whole assessment phase. A draft of the report elaborated by the HTA department is then sent for comments/validati on to the TAG. Then the TAG seats with INEAS to discuss assessment's findings (appraisal). During that meeting a consensus on recommendations is reached, then the final validated report including recommendations is communicated to the benefit package committee to facilitate its decision.				group (TAG) including representatives of ministry of health and other stakeholders is appointed and consulted by INEAS during the whole assessment phase. A draft of the report elaborated by the HTA department is then sent for comments/validati on to the TAG. Then the TAG seats with INEAS to discuss assessment's findings (appraisal). During that meeting a consensus on recommendations is reached, then the final validated report including recommendations is communicated to the ministry of health to facilitate its decision.
Recommendation	See above	See above	See above	See above	See above

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Tunisia - HTA Country/Area Profile



Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	Yes	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	No	Do you assess impact?	N/R
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	Yes		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	1 to 5	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	Yes	If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	6-12 months
In the last 12 months, approximately how many assessments were performed?	4



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	Yes
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Tunisia - HTA Country/Area Profile



	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	No	Yes	Yes	Yes	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Data Availability
	Rank 2	Mandate from Policy Authority		Rank 2	Dedicated human resources
	Rank 3	Qualified human resources		Rank 3	N/R
	Rank 4	N/R		Rank 4	N/R
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Tuvalu - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	Yes
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	N/R	N/R	N/R	N/R	N/R
Assessment	National Drug & therapeutic Committee	N/R	NDTC	N/R	Senior Health Management
Recommendation	NDTC	N/R	NDTC	N/R	Senior Health Management

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Tuvalu - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20
Allocated public sector budget?	No

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	1-3 months
In the last 12 months, approximately how many assessments were performed?	6



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	N/R
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	N/R
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	Yes



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA
	Rank 2	Qualified human resources
	Rank 3	Institutionalization of HTA
	Rank 4	Political support
	Rank 5	Mandate from Policy Authority
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	Data Availability
	Rank 3	Knowledge of methods
	Rank 4	Dedicated human resources
	Rank 5	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Ukraine - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Expert committee of MoH	N/R	N/R	N/R	N/R
Assessment	HTA Department of State Expert Cmetre of MOH of Ukraine	N/R	Since 2022_HTA Department of State Expert Cmetre of MOH of Ukraine	N/R	N/R
Recommendation	MoH	N/R	MoH	N/R	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	Yes		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Ukraine - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20
Allocated public sector budget?	No

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	1-3 months
In the last 12 months, approximately how many assessments were performed?	7



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	Yes
If so, what is it?	3 GDP per capita. Are approved in 2021 on March 29 and will be used for HTA
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	No
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	No	No	Yes	No	No



Barriers

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Ukraine - HTA Country/Area Profile



Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Institutionalization of HTA	Barriers to Production Capability	Rank 1	Data Availability
	Rank 2	Mandate from Policy Authority		Rank 2	Dedicated human resources
	Rank 3	Qualified human resources		Rank 3	Budget availability
	Rank 4	Political support		Rank 4	Knowledge of methods
	Rank 5	Awareness/Advocacy of the importance of HTA		Rank 5	Other Issues
	Rank 6	Other Issues			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





United Arab Emirates - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	Yes
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		N/R

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	Formulary Management

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	The Ministry of Health and Prevention/ Emirate Local Health Authorities	The Ministry of Health and Prevention/ Emirate Local Health Authorities/ Market	The Ministry of Health and Prevention/ Emirate Local Health Authorities	The Ministry of Health and Prevention/ Emirate Local Health Authorities	The Ministry of Health and Prevention/ Emirate Local Health Authorities
Assessment	The Ministry of Health and Prevention/ Emirate Local Health Authorities	The Ministry of Health and Prevention/ Emirate Local Health Authorities/ Market	The Ministry of Health and Prevention/ Emirate Local Health Authorities	The Ministry of Health and Prevention/ Emirate Local Health Authorities	The Ministry of Health and Prevention/ Emirate Local Health Authorities
Recommendation	The Ministry of Health and Prevention/ Emirate Local Health Authorities	The Ministry of Health and Prevention/ Emirate Local Health Authorities/ Market	The Ministry of Health and Prevention/ Emirate Local Health Authorities	The Ministry of Health and Prevention/ Emirate Local Health Authorities	The Ministry of Health and Prevention/ Emirate Local Health Authorities

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





United Arab Emirates - HTA Country/Area Profile



Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	6 to 20	Are any resources received through private funding?	No Private Funding
Allocated public sector budget?	Yes	If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	1-3 months
In the last 12 months, approximately how many assessments were performed?	46



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	No
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	Yes
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



United Arab Emirates - HTA Country/Area Profile



	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Data Availability
	Rank 2	Mandate from Policy Authority		Rank 2	Dedicated human resources
	Rank 3	Institutionalization of HTA		Rank 3	Knowledge of methods
	Rank 4	Qualified human resources		Rank 4	Budget availability
	Rank 5	Political support		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



United Kingdom - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	Yes
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	NICE	NICE	NICE	NICE	DHSC, JCVI, PHE
Assessment	NICE	NICE	NICE	NICE	DHSC, JCVI, PHE
Recommendation	NICE	NICE	NICE	NICE	DHSC, JCVI, PHE

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	Yes
	National Health Service	Yes		
	Patient Organizations	Yes		
	Civil Society	Yes		
	Other	Yes		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	More than 100	Are any resources received through private funding?	Yes
Allocated public sector budget?	Yes	If so, what percentage?	11

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





United Kingdom - HTA Country/Area Profile



Assessments

Question	Response
How long does the assessment process take on average?	6-12 months
In the last 12 months, approximately how many assessments were performed?	150



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	Yes
Do you have a database of health technology costs or prices?	Yes
Is there an officially endorsed cost-effectiveness threshold?	Yes
If so, what is it?	Technology appraisals and diagnostic assessment programme: technologies with a most plausible ICER of or below between £20,000 - £30,000 per QALY gained are usually considered a good use of NHS resources Highly specialised technologies: Below a most plausible ICER of £100,000 per QALY gained, the decision to recommend the use of a highly specialised technology is normally based on the cost-effectiveness estimate with respect to the acceptability of a technology as an effective use of NHS resources The Medical technologies evaluation programme considers technologies that are cost neutral or cost saving to the NHS
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	Yes	Yes	Yes	Yes	No



Barriers

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





United Kingdom - HTA Country/Area Profile



Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Other Issues	Barriers to Production Capability	Rank 1	Data Availability
	Rank 2	Mandate from Policy Authority		Rank 2	Dedicated human resources
	Rank 3	N/R		Rank 3	N/R
	Rank 4	N/R		Rank 4	N/R
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





United Republic of Tanzania - HTA Country/Area Profile¹



Institutions & governance

Question	Response
Has a systematic process to support healthcare decision-making?	No
Please describe your health-care decision making process below.	Data is collected through HMIS to guide for decision making
Can you indicate whether there are plans for implementing a systematic formal process and if so, what that time-frame is?	There will be a process in place in 3-5 years
Any prioritization criteria used to determine which health technologies and interventions are considered in government health schemes in the country?	No
Is evidence collected for making decisions about the inclusion or exclusion of health technologies and interventions?	No
Are there any formal or informal procedures, rules, thresholds, or laws that factor in to the decision-making related to health technologies and interventions?	No

Question	Entity	Title/Function	Response
Entities(e.g. organizations/individuals/officials) involved in decisions regarding inclusion or exclusion of health technologies and interventions:	Entity 1	Title of Entity	N/R
		Functions Performed	N/R
	Entity 2	Title of Entity	N/R
		Functions Performed	N/R
	Entity 3	Title of Entity	N/R
		Functions Performed	N/R
	Entity 4	Title of Entity	N/R
		Functions Performed	N/R
	Entity 5	Title of Entity	N/R
		Functions Performed	N/R

Question	Option	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	No
	Other	N/R

Question	Response
Provisions for revising decisions about health technologies and interventions once they are made.	No
Mechanism for translation or contextualization of evidence?	No

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



United Republic of Tanzania - HTA Country/Area Profile¹



Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Qualified human resources
	Rank 2	Awareness/Advocacy of the importance of HTA
	Rank 3	Institutionalization of HTA
	Rank 4	Mandate from Policy Authority
	Rank 5	Political support
	Rank 6	Other Issues

Question	Ranking	Response
Barriers to Production capability	Rank 1	Dedicated human resources
	Rank 2	Knowledge of methods
	Rank 3	Budget availability
	Rank 4	Data Availability
	Rank 5	Other Issues

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



United States of America - HTA Country/Area Profile¹



Institutions & governance

Question	Response
Has a systematic process to support healthcare decision-making?	No
Please describe your health-care decision making process below.	In the U.S. the process is very decentralized with a variety of processes in place at different government agencies, states, and private health plans
Can you indicate whether there are plans for implementing a systematic formal process and if so, what that time-frame is?	There is no plan to implement such a process
Any prioritization criteria used to determine which health technologies and interventions are considered in government health schemes in the country?	Yes
Is evidence collected for making decisions about the inclusion or exclusion of health technologies and interventions?	Yes
Are there any formal or informal procedures, rules, thresholds, or laws that factor in to the decision-making related to health technologies and interventions?	N/R

Question	Entity	Title/Function	Response
Entities(e.g. organizations/individuals/officials) involved in decisions regarding inclusion or exclusion of health technologies and interventions:	Entity 1	Title of Entity	AHRQ EPC program https://www.ahrq.gov/research/findings/evidence-based-reports/overview/index.html
		Functions Performed	systematic review
	Entity 2	Title of Entity	VA evidence synthesis program https://www.hsrd.research.va.gov/publications/esp/
		Functions Performed	systematic review
	Entity 3	Title of Entity	ICER https://icer.org/
		Functions Performed	systematic review, cost effectiveness
	Entity 4	Title of Entity	Medicare Coverage Group https://www.cms.gov/medicare/coverage/coveragegeninfo
		Functions Performed	prioritization and coverage decisions
	Entity 5	Title of Entity	N/R
		Functions Performed	N/R

Question	Option	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	No
	Planning and budgeting	No
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	No
	Public Procurement of Medicines	No
	Protocols for public health programmes	No

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



United States of America - HTA Country/Area Profile¹



Functions for which decision-making information is gathered?	Other	we do HTA/systematic review only, others use the info for the functions above
--	-------	---

Question	Response
Provisions for revising decisions about health technologies and interventions once they are made.	Yes
Mechanism for translation or contextualization of evidence?	Yes
Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	No
Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Political support
	Rank 2	Other Issues
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production capability	Rank 1	Data Availability
	Rank 2	Budget availability
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R

1. As this country/area responded no to having a systematic process to support healthcare decision-making, a different set of select questions was administered.

2. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

3. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Uruguay - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		Yes
Existence of standard methodology or process guideline?		Yes
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Sanitary Evaluation Division - Specialized Unit for Technology Evaluation of the Ministry of Social Welfare, National Resource Fund	Sanitary Evaluation Division - Specialized Unit for Technology Evaluation of the Ministry of Social Welfare, National Resource Fund	Sanitary Evaluation Division - Specialized Unit for Technology Evaluation of the Ministry of Social Welfare, National Resource Fund	Sanitary Evaluation Division - Specialized Unit for Technology Evaluation of the Ministry of Social Welfare, National Resource Fund	Sanitary Evaluation Division - Specialized Unit for Technology Evaluation of the Ministry of Social Welfare, National Resource Fund
Assessment	Health Assessment Division - Specialized Unit for Technology Assessment of the Ministry of Social Welfare, National Fund for Health Resources /	Sanitary Evaluation Division - Specialized Unit for Technology Evaluation of the Ministry of Social Welfare, National Resource Fund	Sanitary Evaluation Division - Specialized Unit for Technology Evaluation of the Ministry of Social Welfare, National Resource Fund	Sanitary Evaluation Division - Specialized Unit for Technology Evaluation of the Ministry of Social Welfare, National Resource Fund	Sanitary Evaluation Division - Specialized Unit for Technology Evaluation of the Ministry of Social Welfare, National Resource Fund
Recommendation	Sanitary Evaluation Division - Specialized Unit for Technology Evaluation of the Ministry of Social Welfare, National Resource Fund	Sanitary Evaluation Division - Specialized Unit for Technology Evaluation of the Ministry of Social Welfare, National Resource Fund	Sanitary Evaluation Division - Specialized Unit for Technology Evaluation of the Ministry of Social Welfare, National Resource Fund	Sanitary Evaluation Division - Specialized Unit for Technology Evaluation of the Ministry of Social Welfare, National Resource Fund	Sanitary Evaluation Division - Specialized Unit for Technology Evaluation of the Ministry of Social Welfare, National Resource Fund

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Uruguay - HTA Country/Area Profile



Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	Yes	Mechanism for translation or contextualization of evidence?	N/R
	Executive Board of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	Yes	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	Yes	Do you assess impact?	N/R
	National Health Service	Yes		
	Patient Organizations	Yes		
	Civil Society	Yes		
	Other	N/R		



Available Resources

Question	Response	Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R	Are any resources received through private funding?	N/R
Allocated public sector budget?	No	If so, what percentage?	N/R



Assessments

Question	Response
How long does the assessment process take on average?	N/R
In the last 12 months, approximately how many assessments were performed?	38



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	N/R
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	No



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/A
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	No

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Uruguay - HTA Country/Area Profile



	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA	Barriers to Production Capability	Rank 1	Budget availability
	Rank 2	N/R		Rank 2	N/R
	Rank 3	N/R		Rank 3	N/R
	Rank 4	N/R		Rank 4	N/R
	Rank 5	N/R		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Viet Nam - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	No
Do you refer to this as HTA?		N/R
Existence of standard methodology or process guideline?		N/A
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		Yes

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	No
	Objectives for pay-for-performance schemes	No
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	No
	Protocols for public health programmes	No
	Other	N/R

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/ Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Related stakeholders	Related stakeholders	Related stakeholders	Related stakeholders	Related stakeholders
Assessment	Academic organization	Academic organization	Academic organization	Academic organization	Academic organization
Recommendation	Dept. of Health Insurance	Administration of Medical Service	Dept. of Medical Device	Dept. of Medical Device	N/R

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	Yes
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	No
	Department/Ministry of Health	Yes	Do you assess impact?	No
	National Health Service	Yes		
	Patient Organizations	Yes		
	Civil Society	Yes		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Viet Nam - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	N/R
Allocated public sector budget?	Yes

Question	Response
Are any resources received through private funding?	Yes
If so, what percentage?	8



Assessments

Question	Response
How long does the assessment process take on average?	6-12 months
In the last 12 months, approximately how many assessments were performed?	5



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	N/R
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	Yes
If so, what is it?	Currently using WHO recommended cost-effectiveness thresholds comparing with country GDP: =< 1GDP: Very cost - effectiveness 1-3 GDP: Cost Effectiveness >3 GDP: Not cost effectiveness
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	No



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	N/R
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	No	No	No	No	No	No



Barriers

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Viet Nam - HTA Country/Area Profile



Question	Ranking	Response	Question	Ranking	Response
Barriers to Use	Rank 1	Institutionalization of HTA	Barriers to Production Capability	Rank 1	Dedicated human resources
	Rank 2	Mandate from Policy Authority		Rank 2	Knowledge of methods
	Rank 3	Awareness/Advocacy of the importance of HTA		Rank 3	Data Availability
	Rank 4	Political support		Rank 4	Budget availability
	Rank 5	Qualified human resources		Rank 5	N/R
	Rank 6	N/R			

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Zambia - HTA Country/Area Profile



Institutions & Governance

Question	Options	Response
Has a systematic process to support healthcare decision-making?	National Level	Yes
	Subnational Level	Yes
Do you refer to this as HTA?		No
Existence of standard methodology or process guideline?		No
Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions?		No

Question	Options	Response
Functions for which decision-making information is gathered?	Clinical practice guidelines	Yes
	Planning and budgeting	Yes
	Pricing/pricing negotiations of medical technologies	No
	Indicators of quality of care	Yes
	Objectives for pay-for-performance schemes	Yes
	Design of Health Benefit Packages	Yes
	Public Procurement of Medicines	Yes
	Protocols for public health programmes	Yes
	Other	For policies and strategic plans as well

Organizations responsible for assessment, appraisal, and recommendation	Pharmaceutical/Medicines	Medical Procedures	Medical Devices	Diagnostic Tests	Population Level Health Interventions
Appraisal	Ministry of Health -HQ	Ministry of Health HQ	Ministry of Health HQ	Ministry of Health HQ	Ministry of Health PHOs and DHOs
Assessment	ZAMMSA and ZAMRA	MoH Clinical Care Directorate	MoH - Infrastructure Directorate	Hospital Laboratories such as the University Teaching Hospital	Provincial and District Health Offices
Recommendation	MoH and Partners	MoH and Partners	MoH and Partners	MoH and Partners	MoH and Partners

Question	Options	Response	Question	Response
Who nominates or selects interventions to be reviewed?	Scientific Committee of the HTA or decision-making body	No	Mechanism for translation or contextualization of evidence?	No
	Executive Board of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context?	Yes
	Director of the HTA or decision-making body	No	Is there a provision for rapid assessment, appraisal and recommendation in an emergency context?	Yes
	Department/Ministry of Health	Yes	Do you assess impact?	Yes
	National Health Service	No		
	Patient Organizations	No		
	Civil Society	No		
	Other	N/R		



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries





Zambia - HTA Country/Area Profile



Question	Response
How many professional staff (FTE) are involved in the HTA body?	1 to 5
Allocated public sector budget?	Yes

Question	Response
Are any resources received through private funding?	No Private Funding
If so, what percentage?	N/A



Assessments

Question	Response
How long does the assessment process take on average?	3-6 months
In the last 12 months, approximately how many assessments were performed?	5



Appraisals

Question	Response
Are there national guidelines for the preparation of economic evaluations?	No
Do you have a database of health technology costs or prices?	No
Is there an officially endorsed cost-effectiveness threshold?	No
If so, what is it?	N/A
Are stakeholders not represented in the appraisal body invited to react/comment?	Yes
Are members of the appraisal body required to provide a declaration of conflict of interest?	Yes



Recommendations

Question	Response
Is there a possibility to appeal against the decision?	No
Is there a separate entity responsible for recommendation after the appraisal process has been conducted?	Yes

	Assessment reports	Minutes of the meetings	Rationale for the decision	Recommendations (or decisions where relevant)	Other, please specify	No outputs from the recommendation process are published
Are the following published and readily available?	Yes	Yes	No	No	No	No



Barriers

Question	Ranking	Response
Barriers to Use	Rank 1	Awareness/Advocacy of the importance of HTA
	Rank 2	Institutionalization of HTA
	Rank 3	Other Issues
	Rank 4	N/R
	Rank 5	N/R
	Rank 6	N/R

Question	Ranking	Response
Barriers to Production Capability	Rank 1	Knowledge of methods
	Rank 2	Other Issues
	Rank 3	N/R
	Rank 4	N/R
	Rank 5	N/R

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries